

JANE V. ALDRICH, PH.D.
Curriculum Vitae
January, 2024

Address:

Department of Medicinal Chemistry
College of Pharmacy
P.O. Box 100485
University of Florida
Gainesville, FL 32610-0485

Phone: (352) 273-8708

FAX: (352) 392-9455

E-mail address: janealdrich@ufl.edu

I. EDUCATION

Graduate: University of Michigan

Ph.D., January, 1983, Interdepartmental Program in Medicinal Chemistry

Thesis Title: Synthesis and Evaluation of 19-Aza and 19-Amino Androstenedione Analogs as
Potential Aromatase Inhibitors

Thesis Advisor: Dr. Raymond E. Counsell

Undergraduate: Michigan State University

B.S., 1976, Biochemistry/Lyman Briggs College

II. EMPLOYMENT

University of Florida, Gainesville, Florida, Professor, Department of Medicinal Chemistry, February,
2015 – present

University of Florida Term Professor, 2019-2022;

Member, University of Florida Health Cancer Center, 2019 – present.

University of Kansas, Lawrence, Kansas

Professor, Department of Medicinal Chemistry, 2001-2015; Adjunct Professor, 2015-2018;

Courtesy Professor, Department of Pharmaceutical Chemistry, 2006-2015;

Associate Member, University of Kansas Cancer Center, 2007-2015;

Sabbatical: Dr. Vadivel Ganapathy's laboratory, Medical College of Georgia, Department of
Biochemistry and Molecular Biology, August – December, 2008. Project: transport of
opioid peptides

Dr. Mary Jeanne Kreek's laboratory, laboratory of Biology of Addictive Diseases, Rockefeller
University, January – August, 2009. Project: *in vivo* evaluation of opioid peptides

University of Maryland, Baltimore, Baltimore, Maryland

Professor, Department of Pharmaceutical Sciences, School of Pharmacy, 1999-2001;

Associate Professor, Department of Pharmaceutical Sciences, 1995-1999;
Associate Director for Peptide Chemistry, Biopolymer Laboratory, Department of Microbiology and Immunology, 1999-2001;
Department of Microbiology and Immunology (secondary appointment), 1999-2001;
Member, Program in Oncology, Greenebaum Cancer Center; 1996-2001;
Adjunct Associate Professor, Institute of Human Virology, Medical Biotechnology Institute, University of Maryland, Baltimore; 1996-1997.

Visiting Professor:

Dr. Douglas Barofsky's laboratory, Oregon State University, Environmental Health Sciences Center, Oregon State University, Corvallis, OR, July, 2000. Project: nanospray electrospray ionization mass spectrometry (ESI-MS) and micro-liquid chromatography-ESI-MS

Dr. David Ferguson's laboratory, University of Minnesota, Department of Medicinal Chemistry, College of Pharmacy, Minneapolis, Minnesota, July-September, 1999. Project: computational modeling of opioid receptors

Oregon State University, Corvallis, Oregon

Associate Professor of Medicinal Chemistry, College of Pharmacy; 1993-1995;
Assistant Professor of Medicinal Chemistry, College of Pharmacy; 1987-1993;
Affiliated Faculty, The Center for Gene Research and Biotechnology, 1987-1995, and the Molecular and Cellular Biology Graduate Program, 1990-1995.

California State University, Sacramento, Sacramento, California

Assistant Professor of Chemistry (Area: Biochemistry), Department of Chemistry, 1986-1987.

University of Minnesota, College of Pharmacy, Minneapolis, Minnesota

National Institutes of Health Postdoctoral Fellow, 1984 – January 1986;

Research Specialist, January, 1983 – 1984.

Project: Synthesis and evaluation of opioid peptide analogues

Advisor: Dr. Philip S. Portoghese

Honors and Awards

Faculty: Plenary lecture, 4th International Symposium on Pharmacology and Medicinal Chemistry, Rio de Janeiro, Brazil, December 8, 2023.

University of Florida College of Pharmacy Outstanding Teaching Team, Year 6, Award, May, 2022.

Philip S. Portoghese Lecture, University of Minnesota, Department of Medicinal Chemistry, 2021-2022.

American Chemical Society Fellow, 2019.

University of Florida Term Professor, 2019-2022.

Plenary lecture, Royal Australian Chemical Institute Medicinal Chemistry and Chemical Biology 2018 Conference, Brisbane, Australia, November 21, 2018.

Keynote speaker, 3rd Asian Conference on Pharmaceutical Sciences, July 3, 2018, Bali, Indonesia.

University of Florida College of Pharmacy Outstanding Teaching Team, Year 3, Award, May, 2018.

University of Florida College of Pharmacy Teaching and Service Excellence Award, October, 2017; Teacher Service Award, October, 2018.
Distinguished alumni award, Lyman Briggs College, Michigan State University, May 4, 2013.
Leroy B. Townsend lecturer, Department of Medicinal Chemistry, University of Michigan, May 17, 2012.
Independent Scientist Award, National Institute on Drug Abuse, September 1, 1998 - August 31, 2009.
Nominated for Satoh Memorial International Award by Amy Newman, National Institute on Drug Abuse, 2006 and 2008.
Nominated for duVigneaud Award of the American Peptide Society by Lenore Martin, 2007.
Outstanding Professor, junior class, Oregon State University College of Pharmacy, 1991-1992.

Postdoctoral: National Institutes of Health Postdoctoral Fellowship, 1984-1986.

Graduate: National Institutes of Health Training Grants:
Medicinal Chemistry, 1981-1982, Reproductive Endocrinology, 1980-1981;
Rackham Thesis Grant (chosen for partial funding by Sigma Xi in recognition of proposal's outstanding merit), 1979-1980;
American Foundation for Pharmaceutical Education Fellowship, 1977-1980;
R.C. Gibbs Scholarship (second year fellowship sponsored by Phi Kappa Phi, one awarded nationally), 1977-1978;
Phi Kappa Phi Fellowship, 1976-1977;
Michigan College Fellowship, 1976-1977.

III. PROFESSIONAL ACTIVITIES

A. National Offices Held

American Chemical Society, Medicinal Chemistry Division, Councilor 2014-2025, Past Chair of Division, 2001, Chair of Division 2000, Vice-Chair of Division 1999.
American Peptide Society, Past President 2007-2009, President 2005-2007, President-Elect 2003-2005, Councilor 2001-2007.
American Association of Colleges of Pharmacy, Chemistry Section, Secretary, 1994-1996.

B. Symposia and Meetings Chaired and Organized:

Meeting and symposia organized:

- “The Opioid Crisis and the Quest for Superior Analgesics without Addiction,” moderator, American Chemical Society webinar, June 21, 2018.
- “Addiction: The Unmet Medical Need of the 21st Century,” Co-organizer, 254th American Chemical Society National meeting, Medicinal Chemistry division, Washington, DC, August 21, 2017.
- “Advances in Therapeutic Design,” Co-Chair and co-organizer, International Narcotic Research Conference, Phoenix, AZ, June 15-19, 2015.

- “Medicinal Chemistry of Opioid Peptides,” Chair and organizer, International Narcotic Research Conference, Kansas City, MO, July 15-20, 2012; Program Committee member.
- Gordon Research Conference on the Chemistry and Biology of Peptides,
Co-Chair for 2004 meeting,
Co-Vice Chair for 2002 meeting.
- Young Investigators Symposium, Chair and organizer, 16th American Peptide Symposium, Minneapolis, MN, June 26, 1999.
- “Prodrugs and Drug Targeting,” Chair and organizer, symposium, 26th National Medicinal Chemistry Symposium, Richmond, VA, June 17, 1998.
- “Cysteine Proteases,” Chair and organizer, symposium, 214th American Chemical Society National meeting, Medicinal Chemistry Division, Las Vegas, NV, September 11, 1997.

Sessions chaired:

- Keynote Session: “Exploration of Protein Function,” Chemistry and Biology of Peptides Gordon Research Conference, October 30, 2022.
- “Peptides in Delivery,” American Peptide Symposium, Whistler, BC, Canada, June 11-16, 2022.
- Young Investigators Symposium, session co-chair, European Peptide Symposium, Dublin, Ireland, August 26-30, 2018.
- “Macrocycles,” session co-chair, American Peptide Symposium, Orlando, FL, June 20-25, 2015.
- Zing Peptide Chemistry conference, Xcaret, Mexico, November 3-6, 2012, session co-chair.
- “Peptide Materials Science,” session co-chair, 22nd American Peptide Symposium, San Diego, CA, June 25-30, 2011.
- Session 19, 5th International Peptide Symposium, Kyoto, Japan, December 4-9, 2010.
- “SPPS of Difficult/Complex Peptides,” 2nd International Modern Solid Phase Peptide Synthesis and Its Applications Symposium, Gold Coast, Queensland, Australia, October 8-11, 2009.
- “Chemical Biology I”, session co-chair, 21st American Peptide Symposium, Bloomington, IN, June 7-12, 2009.
- 20th American Peptide Symposium, Montreal, Quebec, Canada, June 26-30, 2007
Makineni Award Lecture session chair,
“Peptidomics and Proteomics,” session co-chair,
“Peptides and Diagnostics, Probes, and Biomarkers,” session co-chair.
- Predoctoral Award Symposium, presider, 220th American Chemical Society, Washington, DC, August 20-24, 2000.
- Predoctoral Award Symposium, presider, 218th American Chemical Society, New Orleans, LA, August 22-26, 1999.
- “Combinatorial Approaches to Biology,” Co-chair (invited), panel discussion,
“Bioengineering: Building the Future of Biology and Medicine,” sponsored by NIH Bioengineering Consortium, National Institutes of Health campus, Bethesda, MD, February 28, 1998.
- Young Investigators Symposium, Co-Chair, 15th American Peptide Symposium, Nashville, TN, June 14, 1997.

C. Committee Service

Grant Review Committees:

- National Institutes of Health Drug Discovery for the Nervous System (DDNS) and Molecular Probes Study Sections, chair, July 1, 2017-June 30, 2019; member, July 1, 2015 – June 30, 2019;
- National Institutes of Health Special Emphasis Panel, Pain Therapeutics, chair, January 5, 2024;
- National Institute on Drug Abuse Special Emphasis Panel, Advancing Validated Drug Targets for Substance Use Disorders National Institute of Neurological Disorders and Stroke Special (R41-R44), June 28, 2022;
- National Institute of Neurological Disorders and Stroke Special Emphasis Panel, HEAL Initial Translation Efforts for Non-addictive Analgesic Therapeutics Development (U19), February 23-24, 2022;
- National Institutes of Health Member Conflicts Special Emphasis Panel, December 8, 2021;
- National Institute of Neurological Disorders and Stroke Special Emphasis Panel, HEAL Initiative Non-addictive Analgesic Therapeutics Development (UG3/UH3), March 15, 2021;
- National Institute on Drug Abuse Special Emphasis Panels, Step Up for Substance Use Disorders U18 grant review, June 9, 2020;
- National Institute on Drug Abuse P01 reviews, Pain and Drug Addiction (teleconferences), March 5, 2020, March 15, 2019, December 3, 2018, April 3, 2018, September 8, 2016, November 17, 2015, September 16-17, 2014 and January 22-23, 2014 (internet assisted review);
- National Institutes of Health Molecular Neuropharmacology and Signaling (MNPS) Study Section, June, 2017, mail reviewer;
- National Institute of Health-Industry Program, New Therapeutic Uses pre-application review, August 22, 2014 (internet assisted review);
- National Institute of Health Chemistry, Biochemistry and Biophysics Fellowship Review Committee, November 14-15, 2013;
- National Institute on Drug Abuse Contract Review, March 18, 2013;
- National Institutes of Health CSR College of Reviewers, 2010-2012;
- National Institutes of Health, Molecular Probes study section, ad hoc member, October 18, 2011;
- National Institutes of Health, Biological Chemistry and Macromolecular Biophysics, Member Conflict Panel, August 3, 2011;
- NIAAA Neuroscience Review Subcommittee, ad hoc member, March 8, 2011;
- National Institutes of Health Special Emphasis Panel, RC4 grants, mail reviewer, May, 2010;
- National Institutes of Health Special Emphasis Panel on Biochemistry and Biophysics, mail reviewer, August 20-21, 2009;
- Neuroscience Drug Discovery study section, mail reviewer (Challenge grants), June, 2009;
- National Institute on Drug Abuse Contract Review, May 28, 2008;
- National Institute on Drug Abuse (NIDA) Medications Development (NIDA-L) Study Section, ad hoc member, March 12, 2008;
- National Institutes of Health Neuroscience Drug Discovery Study Section, ad hoc member, July 31, 2006;

National Institutes of Health Drug Discovery & Molecular Pharmacology Study Section, ad hoc member, November 1-2, 2005;
National Institute on Drug Abuse Special Emphasis Panel (SEP), Program Project grants, March 17, 2003;
National Institute on Drug Abuse Training and Career Development Special Emphasis Panel, March 8, 2000;
National Institute of Environmental Health Sciences, Board of Scientific Counselors, ad hoc member, review of Laboratory of Computational Biology and Risk Assessment (primary reviewer for Peptide Neurochemistry laboratory, Dr. Lawrence Lazarus PI), Research Triangle Park, NC, October 17-19, 1999;
U.S. Army Materials and Medical Command Breast Cancer Program, ad hoc grant reviewer, September 24, 1998;
Chemistry and Related Sciences Special Emphasis Panel (fellowship applications), National Institutes of Health, March 12, 1997;
U.S. Army Materials and Medical Command Breast Cancer Program, grant review, September 8-10, 1996;
National Institute on Drug Abuse, contract review, "Synthesis and Distribution of Opioid and Related Peptides," May 23, 1996;
Special study section, SBIR grant review, National Institutes of Health, November 13-14, 1995;
Center for AIDS Research, center grant applications, National Institute of Allergy and Infectious Diseases, December 1-3, 1993;
National Institute on Drug Abuse, program project grant application, November 18, 1993;
"Structural Biology as Applied to the Problem of Targeted Drug Design for the Treatment of AIDS," program project grant applications, National Institute of General Medical Sciences, July 9-10, 1992 and January 27, 1993.
American Foundation for Pharmaceutical Education (AFPE), Board of Grants, 2017-2019.

Also grant reviewer for:

University of Illinois Chicago, 2019;
Medical Research Council, United Kingdom, 2018;
American Chemical Society Petroleum Research Fund, 2007, 2005, and 1998;
National Science Foundation, 2012, and 1997-1999;
Medical Research Council of Canada, 1997.

Professional Societies:

American Chemical Society, Committee on Science member, 2021-2026; associate, 2019-2020; Committee on Chemistry and Public Affairs associate, 2016-2018; Divisional Activities Committee associate, 2015.
ACS National Award selection committee, member, 2016-2018, 2021-2023; chair, 2020.

Medicinal Chemistry Division:

Executive Committee, 2014-2025, 1999-2001;
Diversity Committee, 2014 - present;
Hall of Fame Selection Committee, 2015, 2016, 2018 and 2019;
Officers Nominating Committee, 2003-2004, 2018;
Division of Medicinal Chemistry Award Selection Committee, 2004;
Graduate Fellowship Committee, Chair 2001, member 2000 and 1996-1998;

Long Range Planning Committee, Chair 1999; member 1995-1997;
Portoghese Lectureship Selection Committee, 2016-2018;
National Awards Canvassing Committee for the Alfred Burger Award in Medicinal Chemistry, 2016 and 2018.

American Peptide Society:

American Peptide Society national award selection committees member, 2020, 2022, 2023;
International Liaison Committee meeting, American Peptide Society representative, Dublin, Ireland, August 30, 2018; San Diego, CA, June 27, 2011; Bloomington, IN, June, 2009; and Gdansk, Poland, September 6, 2006;
Membership Committee Chair, 2003-2005;
Peptide Science Editorial Committee member (responsible for identifying a new senior editor for the Society journal *Biopolymers (Peptide Science)*), 2003
Student Affairs Committee, Chair, 1995-1999, Co-chair, 1993-1995;
Award Selection Committee, member 1999, 2006 and 2011;
Publications Committee, member 1995-1999.

Sato Memorial International Award (Pharmaceutical Society of Japan) selection committee, 2019 – present;

Federation of American Societies for Experimental Biology (FASEB), Executive Office Advisory Committee, 2005 – 2007;

American Association of Colleges of Pharmacy:

Volwiler Research Achievement Award Selection Committee, member 1999;
Chemistry Section:
Nominations Committee, member 1993-1994 and 1996-1997;
Membership Committee, member 1992-1993.

Other:

National Institute on Drug Abuse, NIDA Drug Supply request reviewer, 2021.
Oregon Methadone Advisory Committee, November 1993 – June 1994.
Phi Kappa Phi Honor Society, Public Relations Officer, Oregon State University Chapter, 1993 - 1994.

D. Editorial and Reviewer Activities

Editorial Activities:

Editor, *Letters in Peptide Science*, 1994-2004.
Guest editor, special issue, Young Investigators Symposium from the 15th American Peptide Symposium, *Letters in Peptide Science*, vol. 6, number 1, January, 1999.

Editorial Advisory Boards:

ACS Medicinal Chemistry Letters, 2021-2022.
Journal of Medicinal Chemistry, 2016-2018 and 2000-2004.
Peptide Science, 2006 – present.
International Journal of Peptide Research and Therapeutics, 2004 – present.
Journal of Peptide Research, Editorial Board member, June 1997 - 2004;
Transitional Editorial Board member, December 1996 - June 1997.

Reviewer for Scientific Journals:

Reviewer for *Journal of Medicinal Chemistry*, *Biopolymers (Peptide Science)*, *ACS Medicinal Chemistry Letters*, *ACS Chemical Neurosciences*, *Bioorganic and Medicinal Chemistry Letters*, *British Journal of Pharmacology*, and *Journal of Peptide Science* plus other journals (including *Angewandte Chemie*, *Proceedings of the National Academy of Sciences*, *Journal of the American Chemical Society*, *Organic Letters*, *Journal of Organic Chemistry*, *Medicinal Chemistry Research*, *Chemical Biology and Drug Design*, *Chemistry and Biology*, *FASEB Journal*, *Tetrahedron Letters*, *Bioorganic and Medicinal Chemistry*, *European Journal of Medicinal Chemistry*, *Future Medicinal Chemistry*, *Drug Design and Discovery*, *Journal of Neuroscience*, *Neuroscience Letters*, *Molecular Pharmaceutics*, and *Trends in Pharmacological Sciences*).

Reviewed proposal for review for *Chemical Reviews*, 2004.

E. Additional Service to Profession

External reviewer for faculty promotion and/or tenure:

University of North Carolina at Chapel Hill, 2023;
University of Arizona, 2021;
Rensselaer Polytechnic Institute, 2021, 2019;
University of Michigan, 2020;
University of Nebraska, 2020, 2018;
Purdue University, 2019;
University of Redlands, 2018 and 2019 (2 and 4 year reviews);
University of California Los Angeles, 2018;
University of Buffalo, 2017;
South Carolina College of Pharmacy, 2016;
Virginia Commonwealth University, 2015, 2014, 2013, 2009;
University of Nebraska, 2014;
University of Illinois at Chicago, 2012;
Oregon State University, 2011;
Al-Zaytoonah University of Jordan, 2011;
University of Utah, 2009;
University of Queensland (Australia), 2007;
University of Mississippi, 2006;
University of Iowa, 2006;
University of Maryland Baltimore, 2005;
University of Florida, 2003 and 2007;
Ohio State University, 1999;
University of Nebraska, 1998;
Bucknell University, 1997;
University of Georgia (3 year review), 1994.

External reviewer of a graduate program, University of North Carolina.

American Peptide Symposium, Young Investigator Competition, oral presentation judge, 2023;
poster judge, 2019, 2022 and 2023;

Lyman Briggs College, presentation to senior seminar class, April 6, 2022; MSUFCU Annual Research Symposium, poster judge, April 23, 2019;

Florida Annual Meeting and Exhibition (FAME), American Chemical Society, poster judge, 2017 and 2018.

American Association of Colleges of Pharmacy, Chemistry Section, Mentoring Program, mentor for young faculty, 1997-1998.

F. Society Memberships

American Chemical Society, Medicinal Chemistry, Organic Chemistry and Biological Chemistry Divisions

American Peptide Society

Phi Kappa Phi Honor Society

Rho Chi Honor Society

G. Consulting

January- October, 2023, consulting on patents;

November, 2021 – March, 2022, consulting on a patent;

September, 2020 – February, 2021, consulting on patents;

June – November, 2018, expert witness on patent dispute;

1998, New Venture Advisors, Boston, MA, consulting to British biotechnology company.

Expert witness testifying on peptide synthesis in a contract dispute, Eugene, OR, 1990.

IV. SCHOLARLY ACTIVITY

A. Publications

Tanvir Khaliq, Anand Joshi, Sanjeewa N. Senadheera, Susan M. Lunte and Jane V. Aldrich, “Preclinical pharmacokinetic properties of the novel macrocyclic peptide kappa opioid receptor ligands CJ-15,208 and [D-Trp]CJ-15,208,” manuscript in preparation.

Solomon A. Gisemba, Thomas F. Murray, and Jane V. Aldrich, “A bicyclic analog of aroclor is a potent and selective kappa opioid receptor antagonist,” manuscript undergoing revision.

Kristen A. Scherrer, Shainnel O. Eans, Jessica M. Medina, Sanjeewa N. Senadheera, Tanvir Khaliq, Thomas F. Murray, Jay P. McLaughlin and Jane V. Aldrich, “Tryptophan substitution in CJ-15,208 (*cyclo*[Phe-D-Pro-Phe-Trp]) introduces δ -opioid receptor antagonism, preventing antinociceptive tolerance and stress-induced reinstatement of extinguished cocaine-conditioned place preference,” *Pharmaceuticals* **2023**, 1218, doi: 10.3390/ph16091218

Jane Aldrich, Shelley Allen, Erika Araujo, Joanne Bronson, Amanda Bryant-Friedrich, Shana K. Cyr, Erin F. DiMauro, Carolyn Dzierba, , Amanda L. Garner, Gunda I. Georg, Nicole C. Goodwin, Krupanandan Haranahalli, Rong Huang, Katerina Leftheris, Tricia L. May-Dracka, Margaret E. Olson, and Maria-Jesus Blanco, Enhancing the Visibility of Women in the ACS Division of Medicinal Chemistry (ACS MEDI), *J. Med. Chem.* **2023**, 6, 3651-3655 and *ACS Med. Chem. Lett.* **2023**, 14, 345-349.

Ariana C. Brice-Tutt, Shainnel O. Eans, Dmitry Yakovlev, Jane V. Aldrich and Jay P. McLaughlin, “An analog of [D-Trp]CJ-15,208 exhibits kappa opioid receptor antagonism following oral administration and prevents stress effects on reinstatement of morphine-conditioned place preference,” *Pharmacol., Biochem. Behav.* **2022**, 217, 173405, doi: 10.1016/pbb.2022.173405.

- Jane V. Aldrich and Jay P. McLaughlin, "Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development," *Handbook of Experimental Pharmacology, Kappa Opioid Receptors*, Lee-Yuan Liu-Chen and Saaadet Innan, Editors, Springer, **2022**, 271, 198-220, doi: 10.1007/164_2021_519.
- Yuanzi Zhao, Anand A. Joshi, Jane V. Aldrich and Thomas F. Murray, "Quantification of kappa opioid receptor ligand potency, efficacy and desensitization using a real-time membrane potential assay, *Biomed. Pharmacother.* **2021**, 143, 112173, doi: 10.1016/j.biopha.2021.112173
- Wei-Jie Fang, Thomas F. Murray, and Jane V. Aldrich, "Analogues of the κ opioid receptor antagonist arodyn cyclized by ring-closing metathesis retain κ opioid receptor affinity, selectivity and κ opioid receptor antagonism," *Med. Chem. Res.* **2021**, 30, 1397-1407, 10.1007/s00044-021-02758-x.
- Solomon A. Gisemba, Michael J. Ferracane, Thomas F. Murray and Jane V. Aldrich, "Conformational constraint between aromatic residue side chains in the "message" sequence of the peptide arodyn using ring closing metathesis results in a potent and selective kappa opioid receptor antagonist," *J. Med. Chem.* **2021**, 64, 3153-3164, doi: 10.1021/acs.jmedchem.0c01984.
- Ariana C. Brice-Tutt, Sanjeeva N. Senadheera, Michelle L. Ganno, Shainnel O. Eans, Tanvir Khaliq, Thomas F. Murray, Jay P. McLaughlin, and Jane V. Aldrich, "Phenylalanine stereoisomers of CJ-15,208 and [D-Trp]CJ-15,208 exhibit distinctly different opioid activity profiles," *Molecules* **2020**, 25, 3999; doi: 10.3390/molecules25173999.
- Ariana C. Brice-Tutt, Lisa L. Wilson, Shainnel O. Eans, Heather M. Stacy, Chloe A. Simons, Grant Simpson, Jeremy S. Coleman, Michael J. Ferracane, Jane V. Aldrich, and Jay P. McLaughlin, "Multifunctional Opioid Receptor Agonism and Antagonism by a Novel Macrocyclic Tetrapeptide Prevents Reinstatement of Morphine Seeking Behavior," *Br. J. Pharmacol.* **2020**, 177, 4209-4222; doi: 10.1111/bph.15165.
- Michael J. Ferracane, Ariana C. Brice-Tutt, Jeremy S. Coleman, Grant G. Simpson, Lisa L. Wilson, Shainnel O. Eans, Heather M. Stacy, Thomas F. Murray, Jay P. McLaughlin, and Jane V. Aldrich, "Design, Synthesis, and Characterization of the Macrocyclic Tetrapeptide *cyclo*[Pro-Sar-Phe-D-Phe]: A Mixed Opioid Receptor Agonist/Antagonist Following Oral Administration," *ACS Chem. Neurosci.* **2020**, 11, 1324-1336; DOI: 10.1021/acschemneuro.0c00086.
- Solomon A. Gisemba and Jane V. Aldrich, "Optimized Ring Closing Metathesis Reaction Conditions to Suppress Desallyl Side Products in the Solid-Phase Synthesis of Cyclic Peptides Involving Tyrosine(*O*-allyl)," *J. Org. Chem.* **2020**, 85, 1407-1415; DOI: 10.1021/acs.joc.9b02345.
- Jane V. Aldrich, Dmitry Yakovlev, Shainnel O. Eans, Heather M. Stacy, Thomas F. Murray, and Jay P. McLaughlin, "Substitution of Aromatic Residues in the Macrocyclic Opioid Peptide [D-Trp]CJ-15,208 Alters the Opioid Activity Profile *in vivo*," *Proceedings of the 35th European Peptide Symposium*, P. B. Timmons, C. M. Hewage and M. Lebl, editors, European Peptide Society, 2018, pp 61-63.
- Wei-Jie Fang, Thomas F. Murray, and Jane V. Aldrich, "Design, synthesis, and opioid activity of arodyn analogs cyclized by ring-closing metathesis involving Tyr(Allyl)," *Bioorg. Med. Chem.* **2018**, 26, 1157-1161; DOI: 10.1016/j.bmc.2017.11.029.

- Anand A. Joshi, Thomas F. Murray, and Jane V. Aldrich, "Alanine scan of the opioid peptide dynorphin B amide," *Biopolymers (Peptide Sci.)* **2017**, 108 (5), e23026; DOI: 10.1002/bip.23026.
- Archana Mukhopadhyay, Laura Hanold, Hamsa Thayele Purayil, Solomon Gisemba, Sanjeewa Senadheera, and Jane V. Aldrich, "Macrocyclic peptides decrease cMyc protein levels and reduce prostate cancer cell growth," *Cancer Biol. Ther.* **2017**, 18, 571-583; DOI: 10.1080/15384047.2017.1345384.
- Jane V. Aldrich, "Peptide Lead Optimization – Strategies and Tactics " in *Peptide-Based Drug Discovery: Challenges and Opportunities*, Ved Srivastava, Ed. Royal Society of Chemistry, London, 2017, pp 192-222.
- Tanvir Khaliq, Todd D. Williams, Sanjeewa N. Senadheera and Jane V. Aldrich, "Development of a robust, sensitive and selective liquid chromatography-tandem mass spectrometry assay for the quantification of the novel macrocyclic peptide kappa opioid receptor antagonist [D-Trp]CJ-15,208 in plasma and application to an initial pharmacokinetic study," *J. Chromatogr. B* **2016**, 1028, 11–15; DOI:10.1016/j.jchromb.2016.05.043.
- Peng Huang, Tatyana Yakovleva, Jane V Aldrich, and Lee-Yuan Liu-Chen, Zyklophin and Norbinaltorphimine, Two Short-acting Kappa Opioid Receptor Antagonists (Zyklophin and LY244296) Exhibited Different Behavioral Effects from the Long-acting Antagonist Norbinaltorphimine in Mouse Anxiety Tests, *Neurosci. Lett.* **2016**, 615, 15-20; DOI: 10.1016/j.neulet.2016.01.017.
- Sunil Sirohi, Jane V. Aldrich, and Brendan M. Walker, "Species Differences in the Effects of the κ -Opioid Receptor Antagonist Zyklophin," *Alcohol* **2016**, 51, 43-49; DOI: 10.1016/j.alcohol.2015.11.012
- Anand A. Joshi, Thomas F. Murray, and Jane V. Aldrich, "Structure-Activity Relationships of the Peptide Kappa Opioid Receptor Antagonist Zyklophin," *J. Med. Chem.* **2015**, 58, 8783-8795; DOI: 10.1021/jm501827k.
- Michael J. Ferracane and Jane V. Aldrich, "Opioid Ligand Binding to Opioid Receptors: Insight and Implications for Peptide Design," *Peptides 2015; Proceedings of the 24th American Peptide Symposium*, Ved Srivastava, Andrei Yudin and Michal Lebl, Eds., American Peptide Society, 2015, pp 22-23; DOI: 10.17952/24APS.2015.022.
- Sanjeewa N. Senadheera and Jane V. Aldrich, "Optimized Method to Generate Synthetically Challenging Macrocyclic Tetrapeptides That Do Not Have a Turn Inducer," *Peptides 2015; Proceedings of the 24th American Peptide Symposium*, Ved Srivastava, Andrei Yudin and Michal Lebl, Eds., American Peptide Society, 2015, pp 125-126; DOI: 10.17952/24APS.2015.125.
- Solomon Gisemba and Jane V. Aldrich, Peptide Ring Closing Metathesis: Minimizing Side Reactions in Aroclor Analogs," *Peptides 2015; Proceedings of the 24th American Peptide Symposium*, Ved Srivastava, Andrei Yudin and Michal Lebl, Eds., American Peptide Society, 2015, pp 177-178; DOI: 10.17952/24APS.2015.177.
- Tatyana Yakovleva and Jane V. Aldrich, "Optimizing a Larger Scale Synthesis of Zyklophin, a Highly Selective Peptide Kappa Opioid Receptor Antagonist," *Proceedings of the 24th American Peptide Symposium*, Ved Srivastava, Andrei Yudin and Michal Lebl, Eds., American Peptide Society, 2015, pp 283-285; DOI: 10.17952/24APS.2015.283.

- J. V. Aldrich, S. N. Senadheera, N. C. Ross, K.A. Reilley, M. L. Ganno, S. E. Eans, T. F. Murray, and J. P. McLaughlin, "Alanine Analogs of [D-Trp]CJ-15,208: Novel Opioid Activity Profiles and Prevention of Drug- and Stress-Induced Reinstatement of Cocaine-Seeking Behavior," *Br. J. Pharmacol.* **2014**, *171*, 3212-3222.
- K. M. DiMattio, T. V. Yakovleva, J. V. Aldrich, A. Cowan and L. Y. Liu-Chen, "Zyklophin, a short-acting kappa opioid antagonist, induces scratching in mice," *Neuroscience Lett.* **2014**, *563C*, 155-159.
- Archana Mukhopadhyay, Kayann Tabanor, Rathnam Chaguturu and Jane V. Aldrich, "Targeting Inhibitor of Protein Phosphatase 2A as a Therapeutic Strategy for Prostate Cancer Treatment," *Cancer Biol. Ther.* **2013**, *14*, 962-972.
- Shainnel O. Eans, Michelle L. Ganno, Kate J. Reilley, Kshitij A. Patkar, Sanjeewa N. Senadheera, Jane V. Aldrich and Jay P. McLaughlin, "The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short acting κ opioid receptor antagonism in the CNS after oral administration," *Br. J. Pharmacol.* **2013**, *169*, 426-436.
- Yan Zhou, Francesco Leri, Stephanie Grella, Jane V. Aldrich, and Mary Jeanne Kreek, "Involvement of dynorphin and kappa opioid receptor in stress-induced reinstatement of heroin seeking in rats," *Synapse* **2013**, *67*, 358-361.
- Jane V. Aldrich, Sanjeewa N. Senadheera, Nicolette C. Ross, Michelle L. Ganno, Shainnel O. Eans, and Jay P. McLaughlin, "The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine seeking behavior," *J. Nat. Prod.* **2013**, *76*, 433-438.
- Courtney D. Kuhnline Sloan, Kenneth L. Audus, Jane V. Aldrich, and Susan M. Lunte, "The permeation of dynorphin A 1-6 across the blood brain barrier and its effect on bovine brain microvessel endothelial cell monolayer permeability," *Peptides* **2012**, *38*, 414-417.
- Courtney D. Kuhnline Sloan, Pradyot Nandi, Tom Linz, Kenneth L. Audus, Jane V. Aldrich, and Susan M. Lunte, "Analytical and biological methods for probing the blood-brain barrier," *Ann. Rev. Anal. Chem.* **2012**, *5*, 505-531.
- Nicolette C. Ross, Kate J. Reilley, Thomas F. Murray, Jane V. Aldrich, and Jay P. McLaughlin, "Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting kappa opioid receptor antagonism," *Br. J. Pharmacol.* **2012**, *165*, 1097-1108.
- Jane V. Aldrich and Jay P. McLaughlin, "Opioid Peptides: Potential for Drug Development," *Drug Discovery Today: Technologies* **2012**, *9*, e23-e31 (invited review).
- Jane V. Aldrich, Santosh S. Kulkarni, Sanjeewa N. Senadheera, Nicolette C. Ross, Kate J. Reilley, Shainnel Eans, Michelle L. Ganno, Thomas F. Murray, and Jay P. McLaughlin, "Unexpected Opioid Activity Profiles of Analogs of the Novel Peptide Kappa Opioid Receptor Ligand CJ-15,208," *ChemMedChem* **2011**, *6*, 1739-1745.
- Anand A. Joshi, Thomas F. Murray, and Jane V. Aldrich, "Structure-Activity Relationships of the Peptide Kappa Opioid Receptor Antagonist Zyklophin," *Peptides. Building Bridges: Proceedings of the American Peptide Symposium*, M. Lebl, Ed., American Peptide Society, 2011, pp 342-343.

- Jane V. Aldrich, Santosh S. Kulkarni, Sanjeeva N. Senadheera, Nicolette C. Ross, Kate J. Reilley, Shai O. Eans, Michelle L. Ganno, and Jay P. McLaughlin, "Orally Active Opioid Peptides as Leads for Drug Development," *Peptides. Building Bridges: Proceedings of the American Peptide Symposium*, M. Lebl, Ed., American Peptide Society, 2011, pp 344-345.
- Sanjeeva N. Senadheera, Santosh S. Kulkarni, Jay P. McLaughlin, and Jane V. Aldrich, "Improved Synthesis of CJ-15,208 Isomers and Their Pharmacological Activity at Opioid Receptors," *Peptides. Building Bridges: Proceedings of the American Peptide Symposium*, M. Lebl, Ed., American Peptide Society, 2011, pp 346-347.
- Wei-Jie Fang and Jane V. Aldrich, "A Convenient Approach to Synthesis of C-terminal N-Alkyl Amides," *Biopolymers (Peptide Sci.)*, **2011**, 96, 715-722.
- Lakshmi Kelamangalath, Shashank M. Dravid, Joju George, Jane V. Aldrich, and Thomas F. Murray, "κ-Opioid receptor inhibition of calcium oscillations in spinal cord neurons," *Mol. Pharmacol.* **2011**, 79, 1061-1071.
- Jane V. Aldrich, Jay P. McLaughlin, and Thomas F. Murray, "Development of Systemically Active Peptides and Potential for Drug Development," *Peptide Science 2010, Proceedings of the 5th International Peptide Symposium*, N. Fujii and Y. Kiso, Eds., Japanese Peptide Society, 2011, p 44.
- Wei-Jie Fang, Marco A. Bennett, and Jane V. Aldrich, "Deletion of Ac-NMePhe¹ from [NMePhe¹]arodyn under Acidic Conditions: 1. Effects of Cleavage Conditions and N-terminal Functionality," *Biopolymers (Peptide Science)* **2011**, 96, 97-102.
- Wei-Jie Fang, Marco A. Bennett, Thomas F. Murray and Jane V. Aldrich, "Deletion of Ac-NMePhe¹ from [NMePhe¹]arodyn under Acidic Conditions: 2. Effects of Substitution on Pharmacological Activity," *Biopolymers (Peptide Science)* **2011**, 96, 103-110.
- Nicolette C. Ross, Santosh S. Kulkarni, Jay P. McLaughlin and Jane V. Aldrich, "Synthesis of CJ-15,208, a novel κ-opioid receptor antagonist," *Tetrahedron Lett.* **2010**, 51, 5020-5023.
- J. V. Aldrich, Kshitij A. Patkar, and Jay P. McLaughlin, "Zyklophin, a systemically active selective kappa opioid peptide receptor antagonist with short duration of action," *Proc. Natl. Acad. Sci. U. S. A.* **2009**, 106, 18396-18401.
- Bhaswati Sinha, Zhengyu Cao, Thomas F. Murray and Jane V. Aldrich, "Discovery of Dermorphin-Based Affinity Labels with Subnanomolar Affinity for Mu Opioid Receptors," *J. Med. Chem.* **2009**, 52, 7372-7375.
- Kshitij A. Patkar, Thomas F. Murray and Jane V. Aldrich, "The Effects of C-Terminal Modifications on the Opioid Activity of [N-BenzylTyr¹]Dynorphin A-(1-11) Analogues," *J. Med. Chem.* **2009**, 52, 6814-6821.
- Wei-Jie Fang, Yanjun Cui, Thomas F. Murray and Jane V. Aldrich, "Design, Synthesis, and Pharmacological Activities of Dynorphin A Analogues Cyclized by Ring-Closing Metathesis," *J. Med. Chem.* **2009**, 52, 5619-5629.
- Jane V. Aldrich and Jay P. McLaughlin, "Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development," *AAPS J.* **2009**, 11, 312-322 (invited review).

- Jane V. Aldrich, Vivek Kumar, Thomas F. Murray, Wei Guang, and Jia Bei Wang, "Dual Labeled Peptides as Tools to Study Receptors: Nanomolar Affinity Derivatives of TIPP (Tyr-Tic-Phe-Phe) as Probes of δ Opioid Receptors," *Bioconj. Chem.* **2009**, *20*, 201-204.
- Kshitij A. Patkar, W. Edward Highsmith, and Jane V. Aldrich, "Solid Phase and Solution Synthesis of NvocLys(CO(CH₂)₅NH-NDB)OCH₂CN, a Trifunctional Fluorescent Lysine Derivative," *Amino Acids* **2009**, *36*, 203-207.
- Jane V. Aldrich, Vivek Kumar, Bhaswati Dattachowdhury, Angela M. Peck, Xin Wang and Thomas F. Murray, "Solid Phase Synthesis and Application of Labeled Peptide Derivatives: Probes of Receptor-Opioid Peptide Interactions," *Int. J. Peptide Res. Ther.* **2008**, *14*, 315-321.
- Laksana Charoenchai, Hongyan Wang, Jia Bei Wang, and Jane V. Aldrich, High Affinity Conformationally Constrained Nociceptin/Orphanin FQ(1-13) Amide Analogues, *J. Med. Chem.* **2008**, *51*, 4385-4387.
- Jane V. Aldrich, "Opioid Peptides" in *Bioactive Peptides*, J. Howl and S. Jones, Eds., Taylor & Francis, 2008, pp 103-136.
- B. Dattachowdhury, T. F. Murray and J. V. Aldrich, "The Synthesis of DAMGO-based Potential Affinity Labels with High Mu Opioid Receptor Affinity and the Formation of Cyclic O-Alkyl Thiocarbamates" in *Peptides for Youth*, E. Escher, W. D. Lubell, and S. Del Valle, Eds., American Peptide Society, *Adv. Exp. Med. Biol.* **2009**, *611*, 265-266.
- S. S. Kulkarni, N. C. Ross, J. P. McLaughlin, and J. V. Aldrich, "Synthesis of Cyclic Tetrapeptide CJ 15,208, A Novel Kappa Opioid Receptor Antagonist" in *Peptides for Youth*, E. Escher, W. D. Lubell, and S. Del Valle, Eds., American Peptide Society, *Adv. Exp. Med. Biol.* **2009**, *611*, 269-270.
- W.-J. Fang, S. S. Kulkarni, T. F. Murray, and J. V. Aldrich, "Design and Synthesis of Cyclic Aroclon Analogues by Ring-Closing Metathesis (RCM) for Kappa Opioid Receptor (KOP) Antagonists" in *Peptides for Youth*, E. Escher, W. D. Lubell, and S. Del Valle, Eds., American Peptide Society, *Adv. Exp. Med. Biol.* **2009**, *611*, 279-280.
- J. V. Aldrich, K. A. Patkar, A. K. Chappa, W. Fang, K. L. Audus, S. M. Lunte, A. N. Carey, and J. P. McLaughlin, "Development of Centrally Acting Peptide Analogs: Structure-Transport Studies and Pharmacological Evaluation of Analogs of the Opioid Peptide Dynorphin A," in *Proceedings of the 4th International Peptide Symposium*, J. Wilce, Ed., www.peptideoz.org, M 64 (www.peptideoz.org/docs/M_64_Jane_Aldrich.pdf).
- A. N. Carey, K. Borozny, J. V. Aldrich and J. P. McLaughlin, "Reinstatement of Cocaine Place-Conditioning Prevented by the Peptide Kappa Opioid Antagonist, Aroclon," *Eur. J. Pharmacol.* **2007**, *569*, 84-89.
- W.-J. Fang, M. A. Bennett, T. F. Murray and J. V. Aldrich, "An Unexpected Side Reaction Involving the Deletion of an Acetylated N-Methyl-Amino Acid from the N-Terminus of Peptides" in *Understanding Biology Using Peptides*, S.E. Blondelle, Ed., American Peptide Society, 2006, pp. 533-534.
- A. M. Peck, V. Kumar, T. F. Murray, and J. V. Aldrich, "Synthesis and Pharmacological Evaluation of Dual Labeled Delta Opioid Receptor Peptides" in *Understanding Biology Using Peptides*, S.E. Blondelle, Ed., American Peptide Society, 2006, pp. 525-526.

- X. Wang, T. F. Murray, and J. V. Aldrich, "Synthesis and Pharmacological Evaluation of a New Generation of TIPP-Derived Dual-Labeled Ligands for Delta Opioid Receptors" in *Understanding Biology Using Peptides*, S.E. Blondelle, Ed., American Peptide Society, 2006, pp. 523-524.
- S. C. Vigil-Cruz, A. M. Peck, and J. V. Aldrich, "Evaluation of Solid Supports and Solvent Conditions for Use with Microwave-Assisted Solid-Phase Peptide Synthesis" in *Understanding Biology Using Peptides*, S.E. Blondelle, Ed., American Peptide Society, 2006, pp. 162-163.
- Kshitij A. Patkar, Xiuzhen Yan, Thomas F. Murray, and Jane V. Aldrich, "[N^a-BenzylTyr¹,cyclo(D-Asp⁵,Dap⁸)dynorphin A-(1-11)NH₂ Cyclized in the "Address" Domain is a Novel κ -Opioid Receptor Antagonist," *J. Med. Chem.* **2005**, *48*, 4500-4503.
- Zoya Marinova, Vladana Vukojevic, Slavina Surcheva, Tatiana Yakovleva, Gvido Cebers, Natalia Pasikova, Ivan Usynin, Loïc Hugonin, Weijie Fang, Mathias Hallberg, Daniel Hirschberg, Tomas Bergman, Ülo Langel, Kurt F. Hauser, Aaladdin Pramanik, Jane V. Aldrich, Astrid Gräslund, Lars Terenius, and Georgy Bakalkin, "Translocation of Dynorphin Neuropeptides across the Plasma Membrane. A Putative Mechanism of Signal Transmission," *J. Biol. Chem.* **2005**, *280*, 26360-26370.
- M. A. Bennett, T. F. Murray, and J. V. Aldrich, "Structure-Activity Relationships of Arodyn, a Novel Acetylated Kappa Opioid Receptor Antagonist," *J. Peptide Res.* **2005**, *65*, 322-332.
- K.F. Hauser, J.V. Aldrich, K.J. Anderson, G. Bakalkin, M.J. Christie, E.D. Hall, P.E. Knapp, S.W. Scheff, I.N. Singh, B. Vissel, A.S. Woods, T. Yakovleva, and T.S. Shippenberg, "Pathobiology of Dynorphins in Trauma and Disease," *Front. Biosci.* **2005**, *10*, 216-235.
- J. V. Aldrich, H. Choi, and T. F. Murray, "An Affinity Label for δ -Opioid Receptors Derived from [D-Ala²]Deltorphin I," *J. Peptide Res.* **2004**, *63*, 108-115.
- B.S. Vig and J.V. Aldrich, "An Inexpensive, Manually Operated, Solid-Phase, Parallel Synthesizer," *Aldrichchimica Acta* **2004**, *37*, 2.
- Balvinder S. Vig, Thomas F. Murray, and Jane V. Aldrich, "Synthesis and Opioid Activity of Side-Chain-to-Side-Chain Cyclic Dynorphin A-(1-11) Amide Analogues Cyclized between Positions 2 and 5. 1. Substitution in Position 3," *J. Med. Chem.* **2004**, *47*, 446-455.
- M.W. Leighty, T.F. Murray, and J.V. Aldrich, "Structure-Activity Relationships of a Novel Cyclic Dynorphin A Analog with Kappa Opioid Receptor Antagonist Activity," in *Peptide Revolution: Genomics, Proteomics, & Therapeutics*, M. Chorev and T.K. Sawyer, Eds., American Peptide Soc., San Diego, 2003, pp 691-692.
- Balvinder S. Vig, Mike Q. Zheng, Thomas F. Murray, and Jane V. Aldrich, "Effects of the Substitution of Phe⁴ in the Opioid Peptide [D-Ala⁸]Dynorphin A-(1-11)NH₂," *J. Med. Chem.* **2003**, *46*, 4002-4008.
- Balvinder S. Vig, Thomas F. Murray, and Jane V. Aldrich, "Synthesis of Novel Basic Head-to-Side-Chain Cyclic Dynorphin A Analogs: Strategies and Side Reactions," *Biopolymers (Peptide Sci.)* **2003**, *71*, 620-637.

- Heekyung Choi, Thomas F. Murray, and Jane V. Aldrich, "Synthesis and Evaluation of Derivatives of Leucine Enkephalin as Potential Affinity Labels for δ Opioid Receptors," *Biopolymers (Peptide Sci.)* **2003**, 71, 552-557.
- Vivek Kumar and Jane V. Aldrich, "A Solid Phase Synthetic Strategy for Labeled Peptides: Synthesis of a Biotinylated Derivative of the δ Opioid Receptor Antagonist TIPP (Tyr-Tic-Phe-PheOH)," *Org. Lett.* **2003**, 5, 613-616.
- Balvinder S. Vig, Thomas F. Murray, and Jane V. Aldrich, "A Novel N-Terminal Cyclic Dynorphin A Analogue *cyclo*^{N,5}[Trp³, Trp⁴, Glu⁵]Dynorphin A-(1-11)NH₂ that Lacks the Basic N-Terminus," *J. Med. Chem.* **2003**, 46, 1279-1282.
- H. Choi, T. F. Murray, and J. V. Aldrich, "Synthesis and Evaluation of Potential Affinity Labels Derived from Endomorphin-2," *J. Peptide Res.* **2003**, 61, 58-62.
- H. Choi, T. F. Murray, and J. V. Aldrich, "Dermorphin-Based Potential Affinity Labels for μ -Opioid Receptors," *J. Peptide Res.* **2003**, 61, 40-45.
- J. V. Aldrich and S. C. Vigil-Cruz, "Narcotic Analgesics," in *Burger's Medicinal Chemistry and Drug Discovery*, 6th Ed., D.J. Abraham, Ed., John Wiley, Inc: New York, 2003, Vol. 6, pp 329-481 (**invited chapter**).
- Marco A. Bennett, Thomas F. Murray, and Jane V. Aldrich, "Identification of Arodyn, A Novel Acetylated Dynorphin A-(1-11) Analogue, as a κ Opioid Receptor Antagonist," *J. Med. Chem.* **2002**, 45, 5617-5619.
- Vivek Kumar, Thomas F. Murray, and Jane V. Aldrich, "Solid Phase Synthesis and Evaluation of Tyr-Tic-Phe-Phe(*p*-NHCOCH₂Br) ([Phe(*p*-bromoacetamide)⁴]TIPP), a Potent Affinity Label for δ Opioid Receptors," *J. Med. Chem.* **2002**, 45, 3820-3823.
- B. Vig, T.F. Murray, and J.V. Aldrich, "Synthesis of Novel N-Terminal Cyclic Dynorphin A Analogues: Strategies and Side Reactions," *Peptides: Wave of the Future* (Proceedings of the 17th American Peptide Symposium/ 2nd International Peptide Symposium), M. Lebl and R.A. Houghten, Eds., American Peptide Soc., 2001, pp. 144-145.
- K. Patkar, T.F. Murray and J.V. Aldrich, "Design and Synthesis of [N-benzylTyr¹]Dyn A-(1-11) Analogs with C-terminal Modification and Evaluation of Their Opioid Activity," *Peptides: Wave of the Future* (Proceedings of the 17th American Peptide Symposium/ 2nd International Peptide Symposium), M. Lebl and R.A. Houghten, Eds., American Peptide Soc., 2001, pp. 687-688.
- C. Sasiela, M. A. Bennett, T.F. Murray and J.V. Aldrich, "C-Terminal Structure-Activity Relationships for the Novel Opioid Peptide JVA-901 (Venorphin)," *Peptides: Wave of the Future* (Proceedings of the 17th American Peptide Symposium/ 2nd International Peptide Symposium), M. Lebl and R.A. Houghten, Eds., American Peptide Soc., 2001, pp. 689-690.
- M.A. Bennett, T. F. Murray, and J.V. Aldrich, "Structure-Activity Relationship Studies of Arodyn, A Novel Dynorphin A-(1-11) Analog," *Peptides: Wave of the Future* (Proceedings of the 17th American Peptide Symposium/ 2nd International Peptide Symposium), M. Lebl and R.A. Houghten, Eds., American Peptide Soc., 2001, pp. 894-895.

- Jane V. Aldrich, Qi Zheng, and Thomas F. Murray, "Dynorphin A Analogues Containing a Conformationally Constrained Phenylalanine Analogue in Position 4: Reversal of Preferred Stereochemistry for Opioid Receptor Affinity and Discrimination of κ vs. δ Receptors," *Chirality* **2001**, *13*, 125-129.
- Vivek Kumar, Thomas F. Murray, and Jane V. Aldrich, "Extended TIP(P) Analogues As Precursors for Labeled δ -Opioid Receptor Ligands," *J. Med. Chem.* **2000**, *43*, 5050-5054.
- Dean Y. Maeda, Fred Berman, Thomas F. Murray, and Jane V. Aldrich, "Synthesis and Evaluation of Potential Affinity Labels Based on the Delta Opioid Receptor Antagonist TIPP," *J. Med. Chem.* **2000**, *43*, 5044-5049.
- Dean Y. Maeda, Jane E. Ishmael, Thomas F. Murray, and Jane V. Aldrich, "Synthesis and Evaluation of N,N-Dialkyl Enkephalin-based Affinity Labels for δ Opioid Receptors," *J. Med. Chem.* **2000**, *43*, 3941-3948.
- Leena Leelaswatanakij and Jane V. Aldrich, "Solid Phase Synthetic Strategy for the Preparation of Peptide-Based Affinity Labels: Synthesis of Dynorphin A Analogues," *J. Peptide Res.* **2000**, *56*, 80-87.
- J. V. Aldrich, Q. Wan, and T. F. Murray, "Novel Opioid Peptides as Kappa Opioid Receptor Antagonists," *Peptides: Chemistry and Biology* (Proceedings of the 16th American Peptide Symposium), G. Barany and G. Fields, Eds., ESCOM: Leiden, 2000, pp. 616-618.
- H. Choi, T. F. Murray, and J. V. Aldrich, "Synthesis and Evaluation of Potential Affinity Labels for Opioid Receptors," *Peptides: Chemistry and Biology* (Proceedings of the 16th American Peptide Symposium), G. Barany and G. Fields, Eds., ESCOM: Leiden, 2000, pp. 42-43.
- Qiang Wan, Thomas F. Murray, and Jane V. Aldrich, "A Novel Acetylated Analogue of Dynorphin A-(1-11)Amide as a κ Opioid Receptor Antagonist," *J. Med. Chem.* **1999**, *42*, 3011-3013.
- Sandra C. Vigil-Cruz and Jane V. Aldrich, "Unexpected Aspartimide Formation During Coupling Reactions Using Asp(OAl) in Solid Phase Peptide Synthesis," *Lett. Peptide Sci.* **1999**, *6*, 71-75.
- Ken Soderstrom, Heekyung Choi, Frederick W. Berman, Jane V. Aldrich, and Thomas F. Murray, "N-Alkylated Derivatives of [D-Pro¹⁰]Dynorphin A-(1-11) are High Affinity Partial Agonists at the Cloned Rat κ -Opioid Receptor," *Eur. J. Pharmacol.* **1997**, *338*, 191-197.
- Heekyung Choi, Thomas F. Murray, Gary E. DeLander, William K. Schmidt, and Jane V. Aldrich, "Synthesis and Opioid Activity of [D-Pro¹⁰]Dynorphin A-(1-11) Analogues with N-Terminal Alkyl Substitution," *J. Med. Chem.* **1997**, *40*, 2733-2739.
- Seksiri Arttamangkul, Jane E. Ishmael, Thomas F. Murray, David K. Grandy, Gary E. DeLander, Brigitte L. Kieffer, and Jane V. Aldrich, "Synthesis and Opioid Activity of Conformationally Constrained Dynorphin A Analogues. 2. Conformational Constraint in the "Address" Sequence," *J. Med. Chem.* **1997**, *40*, 1211-1218.
- Seksiri Arttamangkul, Brian Arbogast, Douglas Barofsky and Jane V. Aldrich, "Characterization of Synthetic Peptide Byproducts from Cyclization Reactions Using On-

- Line HPLC-Ion Spray and Tandem Mass Spectrometry," *Lett. Peptide Sci.* **1997**, 3, 357-370.
- Jane V. Aldrich, "Analgesics" in *Burger's Medicinal Chemistry and Drug Discovery*, Volume 3, 5th edition, Manfred E. Wolff, Ed., John Wiley & Sons, Inc.: New York, 1996; pp. 321-441 (**invited chapter**).
- Ole N. Jensen, Sandhya Kulkarni, Jane V. Aldrich, and Douglas F. Barofsky, "Characterization of Peptide-Oligonucleotide Heteroconjugates by Mass Spectrometry," *Nucleic Acids Res.* **1996**, 24, 3866-3872.
- Jane V. Aldrich, Leena Leelasvatanakij, and Dean Y. Maeda, "Synthetic Strategies for the Preparation of Peptide-Based Affinity Labels" in *Peptides: Chemistry and Biology* (Proceedings of the 14th American Peptide Symposium), T. P. Kaumaya and R. S. Hodges, Eds., Mayflower Scientific Ltd.: West Midlands, England, 1996; pp. 36-38.
- Sandhya N. Kulkarni, Heekyung Choi, Thomas F. Murray, Gary E. DeLander, and Jane V. Aldrich, "The Use of the Message-Address Concept in the Design of Potential Antagonists Based on Dynorphin A," in *Peptides: Chemistry and Biology* (Proceedings of the 14th American Peptide Symposium), T. P. Kaumaya and R. S. Hodges, Eds., Mayflower Scientific Ltd.: West Midlands, England, 1996; pp. 655-656.
- Seksiri Arttamangkul, Thomas F. Murray, Gary E. DeLander, and Jane V. Aldrich, "Synthesis and Opioid Activity of Conformationally Constrained Dynorphin A Analogues. 1. Conformational Constraint in the "Message" Sequence," *J. Med. Chem.* **1995**, 38, 2410-2417.
- S. Arttamangkul, T. F. Murray, G. E. DeLander, and J. V. Aldrich, "Synthesis and Opioid Activity of Conformationally Constrained Dynorphin A Analogues," *Regulatory Pept.* **1994**, 54 (1) (Proceedings of the 25th International Narcotic Research Conference (INRC), North Falmouth, MA, July 16-21, 1994), 13-14.
- D. Y. Maeda, T. F. Murray, J. E. Roth, and J. V. Aldrich, "Synthesis of Enkephalin-Based Affinity Labels for Delta Opioid Receptors," *Regulatory Pept.* **1994**, 54 (1) (Proceedings of the 25th International Narcotic Research Conference (INRC), North Falmouth, MA, July 16-21, 1994), 171-172.
- Sandra C. Story and Jane V. Aldrich, "Side-Product Formation During Cyclization with HBTU on a Solid Support," *Int. J. Peptide Protein Res.* **1994**, 43, 292-296.
- Jane V. Aldrich, "Narcotic Analgesics," *Am. J. Pharm. Educ.* **1993**, 57, 153-161 (invited review).
- Kristin R. Snyder, Thomas F. Murray, Gary E. DeLander and Jane V. Aldrich, "Synthesis and Opioid Activity of Dynorphin A-(1-13)NH₂ Analogues Containing *cis*- and *trans*-4 Aminocyclohexanecarboxylic Acid," *J. Med. Chem.* **1993**, 36, 1100-1103 (publisher's correction pp. 1921-1922).
- H. Choi and J. V. Aldrich, "Comparison of Methods for the Fmoc Solid-Phase Synthesis and Cleavage of a Peptide Containing Both Tryptophan and Arginine," *Int. J. Peptide Protein Res.* **1993**, 42, 58-63.
- Heekyung Choi, Thomas F. Murray, Gary E. DeLander, Valerie Caldwell and Jane V. Aldrich, "N Terminal Alkylated Derivatives of [D-Pro¹⁰]dynorphin A-(1-11) are Highly Selective for κ Opioid Receptors," *J. Med. Chem.* **1992**, 35, 4638-4639.

- Kristin R. Snyder, Sandra C. Story, Mia E. Heidt, Thomas F. Murray, Gary E. DeLander, and Jane V. Aldrich, "Effect of Modification of the Basic Residues of Dynorphin A-(1-13) Amide on κ Opioid Receptor Selectivity and Opioid Activity," *J. Med. Chem.* **1992**, *35*, 4330-4333.
- Sandra C. Story, Thomas F. Murray, Gary E. DeLander, and Jane V. Aldrich, "Synthesis and Opioid Activity of 2-Substituted Dynorphin A-(1-13) Amide Analogues," *Int. J. Peptide Protein Res.* **1992**, *40*, 89-96.
- Heekyung Choi, Gary E. DeLander, Thomas F. Murray, Sonia Anderson, and Jane V. Aldrich, "Synthesis and Opioid Activity of Dynorphin A-(1-13) Analogues Substituted at Positions 2 and 4," in *Peptides: Chemistry and Biology* (Proceedings of the 12th American Peptide Symposium), J. A. Smith and J. E. Rivier, Eds., ESCOM Science Publishers: Leiden, the Netherlands, 1992; pp. 134-135.
- Sandra C. Story and Jane V. Aldrich, "Preparation of Protected Peptide Amides Using the Fmoc Chemical Protocol. Comparison of Resins for Solid Phase Synthesis," *Int. J. Peptide Protein Res.* **1992**, *39*, 87-92.
- Jane V. Aldrich and Sandra C. Story, "Solid Phase Synthetic Strategies for the Preparation of Affinity Labels Derived from Dynorphin A," *New Leads in Opioid Research* (Proceedings of the 21st International Narcotics Research Conference, Noordwijkerhout, The Netherlands, 8-13 July 1990); J. M. van Ree, A. H. Mulder, V. M. Wiegant, T. B. van Wimersma Greidanus, Eds.; Excerpta Medica Congress Series No 914, Elsevier Science Publishers: Amsterdam, 1990; pp 216-218.
- Jane Aldrich Lovett* and Philip S. Portoghese, "Synthesis and Evaluation of Melphalan-Containing N,N-Dialkylenkephalin Analogues as Irreversible Antagonists of the δ Opioid Receptor," *J. Med. Chem.* **1987**, *30*, 1668-1674.
- Jane Aldrich Lovett and Philip S. Portoghese, "N,N-Dialkylated Leucine Enkephalins As Potential δ Opioid Receptor Antagonists," *J. Med. Chem.* **1987**, *30*, 1144-1149.
- Jane Aldrich Lovett and Philip S. Portoghese, "Melphalan-Containing N,N-Dialkylenkephalin Analogs as Potential Irreversible Antagonists of the δ Opioid Receptor," *Progress in Opioid Research*: (Proceedings of the 1986 International Narcotics Research Conference), *National Institute on Drug Abuse Research Monograph*, *75*, J.W. Holaday, P.-Y. Law, and A. Herz, Eds.; DHHS Pub. No. (ADM) 7-1507, U.S. Government Printing Office: Washington, DC, 1986; pp. 185-188.
- M. V. Darby, J. Aldrich Lovett*, R. W. Brueggemeier, M. P. Groziak, and R. E. Counsell, "7 α Substituted Derivatives of Androstenedione as Inhibitors of Estrogen Biosynthesis," *J. Med. Chem.* **1985**, *28*, 803-807.
- Jane Aldrich Lovett, Michael V. Darby, and Raymond E. Counsell, "Synthesis and Evaluation of 19-Aza- and 19-Aminoandrostenedione Analogs as Potential Aromatase Inhibitors," *J. Med. Chem.* **1984**, *27*, 734-740.

* Former name

Publications Other than Refereed Articles

J. V. Aldrich, "President's Message," *Understanding Biology Using Peptides*, S.E. Blondelle, Ed., American Peptide Society, 2006,

J. Aldrich, "Young Investigators Symposium," *Lett. Peptide Sci.* **1999**, 6, 1.

F. Albericio, J. V. Aldrich, E. Atherton, B. M. Dunn, G. B. Fields, and Y Shimonishi, Editorial: "LIPS Symposia in Print and Other Issues," *Lett. Peptide Sci.* **1996**, 3, 1.

B. Patents and patent applications

Jane V. Aldrich, Archana Mukhopadhyay and Laura E. Hanold, "Macrocyclic Peptides Decrease c-Myc Protein Levels and Reduce Cancer Cell Growth," US Patent No. 11,510,964 B2, November 22, 2022; European patent No. 3570863, July 27, 2022; Chinese ZL 201880019278.X, September 19, 2023.

Jane V. Aldrich, Jay P. McLaughlin and Dmitry Yakolev, "Novel Macrocyclic Opioid Peptides," provisional application No. 63/126723 filed December 17, 2020; full application No. PCT/US21/63892 filed December 16, 2021, application WO 2022/150167 A2 published July 14, 2022; national phase application filed June 16, 2023

Jane V. Aldrich and Jeremy Coleman, "Steroidal Compound Derivatives as Therapeutic Agents," provision application 63/127091 filed December 17, 2020; full application PCT/US2021/06412 filed December 17, 2021; WO 2022/133265 A1 published June 23, 2022; national phase application filed June 16, 2023.

Jane V. Aldrich and Michael Ferracane, "Novel Macrocyclic Opioid Peptides," provisional patent application No. 62/658,915 filed April 17, 2018; full application No. PCT/US19/27928 filed April 17, 2019, application WO 2019/204488 A1 published October 24, 2019; U.S. national phase application filed October 15, 2020.

Jane V. Aldrich, Sanjeewa Senadheera and Jay McLaughlin, "Cyclic Tetrapeptide Analogs," provisional patent application No. 62/647287 filed March 23, 2018; full application No. PCT/US19/23698 filed March 22, 2019; U.S. national phase application No. 16/982638 filed September 21, 2020, US Patent application No. US 2021/0024576 A1 published January 28, 2021; U.S. Patent No. 11,820,835 issued November 21, 2023.

Japanese application filed September 23, 2020; European patent application No. 19771690.5 filed October 1, 2020; Indian patent application No. 202017044153 filed October 9, 2020; Chinese application No. CB/P22423CN00 filed November 20, 2020.

Jane V. Aldrich and Laura E. Hanold, "Macrocyclic Peptides and Derivatives Thereof with Opioid Activity," provisional patent application No. 62/520,992 filed June 16, 2017; full application No. PCT/US18/37822 filed June 15, 2018, application WO 2018/232285 published December 20, 2018; U.S. national phase application No. 16622749 filed December 13, 2019, application No. US-2020-0109168-A1 published April 9, 2020; US Patent 11,325,944 B2 issued May 10, 2022.

Jane V. Aldrich and Sanjeewa Senadheera, "Cyclic Tetrapeptide Stereoisomers," US Patent No. 10,259,843 B2, April 16, 2019; European patent EP3166625, May 1, 2019; U.S. application # 16383016 and European application # EP19168888.6, submitted April 12, 2019.

Jane V. Aldrich, Nicolette Ross and Santosh Kulkarni, "Cyclic Tetrapeptides," US Patent No. 8,809,278 B2, August 19, 2014.

Jane V. Aldrich, Kshitij Patkar, and Jay McLaughlin, "Method for Treating and/or Preventing Cocaine Addiction," US Patent application, submitted October, 2008.

Jane V. Aldrich and Vivek Kumar, "Methods of Synthesizing and Using Derivatives of [2-(2-aminoethoxy)ethoxy]acetic Acid," US Patent Application Publication US2005/0187407 A1, University of Maryland Baltimore, divisional application submitted but not granted.

Jane V. Aldrich and Vivek Kumar, "Methods of Synthesizing and Using Derivatives of [2-(2-aminoethoxy)ethoxy]acetic Acid," US Patent No. 7,038,078 B2, University of Maryland Baltimore, May 2, 2006.

C. Presentations at Scientific Meetings

Jane V. Aldrich, "Macrocyclic Tetrapeptides – Versatile Compounds for Potential Drug Development," plenary lecture, 4th International Symposium on Pharmacology and Medicinal Chemistry, Rio de Janeiro, Brazil, December 8, 2023.

J.P. McLaughlin, S.O. Eans, A.C. Brice-Tutt, D. Yakovlev, B.I. Knapp, J. M. Bidlack, and J.V. Aldrich, "Probing analogs of macrocyclic tetrapeptide CJ-15,208 for orally-active kappa opioid receptor antagonism as a potential therapeutic to prevent stress-induced cocaine reinstatement," poster, Society for Neuroscience, Washington, D.C., November 11-15, 2023.

Jane V. Aldrich, "Optimization of Macrocyclic Peptides as Potential Treatments for Substance Abuse," oral presentation, Chemistry and Pharmacology of Drug Abuse, Boston, MA, August 3-4, 2023.

L.E. Hanold and J.V. Aldrich, "An Anti-Proliferative Peptide Downregulates CIP2A and Associated Proteins in Ovarian Cancer," poster, 28th American Peptide Symposium, Scottsdale, AZ, June 24-29, 2023.

Jane V. Aldrich, "Macrocyclic Peptides as Potential Treatments for Substance Abuse," invited lecture, The Wertheim UF Scripps Institute Chemical Biology and 5th UF Drug Discovery Symposium, Jupiter, FL, April 20-21, 2023.

Jane V. Aldrich, Tanvir Khaliq, Shainnel Eans, Ariana C. Brice-Tutt, and Jay P. McLaughlin.. "Pharmacokinetics of macrocyclic tetrapeptide kappa opioid peptide antagonists and their potential for drug development," invited lecture, 7th Conference on the Therapeutic Potential of Kappa Opioids, Bethesda, MD, March 29-31, 2023.

Tanvir Khaliq, Adriana C. Brice-Tutt, Heather M. Stacy, Shainnel O. Eans, Jeremy S. Coleman, Jay P. McLaughlin and Jane V. Aldrich, "Preclinical evaluation of orally bioavailable macrocyclic mixed opioid agonist/antagonist tetrapeptide *cyclo*[Pro-Sar-Phe-D-Phe]," poster, American Chemical Society national meeting, Chicago, IL, August 21-25, 2022.

Jane V. Aldrich, Dmitry Yakolev, Ariana C. Brice-Tutt, Shainnel O. Eans and Jay P. McLaughlin, "Macrocyclic tetrapeptides prevent reinstatement of opioid-seeking behavior," oral presentation, 27th American Peptide Symposium, Whistler, BC, Canada, June 11-16, 2022.

Laura E. Hanold, Asiah L. Creek and Jane V. Aldrich, "Anti-Proliferative Macrocyclic Peptides

- Regulate Proteins in the c-Myc Degradation Pathway,” poster, 27th American Peptide Symposium, Whistler, BC, Canada, June 11-16, 2022.
- Jane V. Aldrich, Tanvir Khaliq and Jay P. McLaughlin, “Macrocyclic peptides: Orally bioavailable peptides for potential drug development,” invited speaker (virtual presentation), American Chemical Society Rocky Mountain Regional Meeting, Tucson, AZ, October 21, 2021.
- Michael J. Ferracane, Jane V. Aldrich and Jay P. McLaughlin, “Rational design, synthesis, conformation analysis, and opioid activity of *cyclo*[Pro-Sar-Phe-D-Phe] and its analogs,” oral presentation, American Chemical Society national meeting, Atlanta, GA, August 22-26, 2021.
- Jane V. Aldrich, Tanvir Khaliq, Michael Ferracane, Jeremy S. Coleman, Shainnel O Eans, Ariana Brice-Tutt and Jay P. McLaughlin, “Pharmacokinetic properties of macrocyclic tetrapeptides and their potential for drug development,” poster, International Narcotic Research Conference, virtual, July 12-14, 2021.
- Ariana C. Brice-Tutt, Shainnel O. Eans, Dmitry Yakolev, Jane V. Aldrich and Jay P. McLaughlin, “Discovery and evaluation of a novel kappa opioid receptor antagonist with potential application in opioid use disorder,” poster, International Narcotic Research Conference, virtual, July 12-14, 2021.
- Jane V. Aldrich, Dmitry Yakovlev, Tanvir Khaliq, Shainnel O. Eans, Heather M. Stacy, Ariana Brice-Tutt, Thomas F. Murray and Jay P. McLaughlin, “Structural modifications to Phe³ in [D-Trp]CJ-15,208 is well tolerated by kappa opioid receptors,” poster, KappaCon 2021, the 6th conference on the therapeutic potential of kappa opioids in pain and addiction, virtual, April 6-9, 2021.
- Jay P. McLaughlin, Ariana C. Brice-Tutt, Lisa L. Wilson, Shainnel O. Eans, Heather M. Stacy, Jeremy S. Coleman, Sanjeewa N. Senadheera, Michael J. Ferracane and Jane V. Aldrich, “Refinement of kappa opioid activity in multifunctional cyclic tetrapeptides facilitates safer analgesics and treatments for substance abuse,” oral presentation, KappaCon 2021, the 6th conference on the therapeutic potential of kappa opioids in pain and addiction, virtual, April 6-9, 2021.
- Laura E. Hanold, Asiah L. Cheek, and Jane V. Aldrich, “Exploring the role of the macrocyclic peptide [D-Trp]CJ-15,208 in the c-Myc degradation pathway,” poster, University of Florida Health Cancer Center Virtual Research Symposium, December 8-10, 2020.
- Ariana C. Brice-Tutt, Shainnel O. Eans, Heather M. Stacy, Dmitry Yakovlev, Jeremy Coleman, Grant Simpson, Mike Ferrecane, Jane V. Aldrich and Jay P. McLaughlin, “Multifunctional mu- and kappa-opioid ligands as potential therapeutics for pain and substance abuse,” College on Problems of Drug Dependence virtual meeting, June 22-24, 2020.
- Ariana C. Brice-Tutt, Lisa L. Wilson, Shainnel O. Eans, Heather M. Stacy, Grant Simpson, Michael Ferracane, Jane V. Aldrich, and Jay P. McLaughlin, “Mixed opioid receptor agonism and antagonism demonstrated by a novel cyclic tetrapeptide prevents drug- and stress-induced reinstatement of morphine- and cocaine-seeking behavior,” International Narcotic Research Conference, New York, NY, July 7-11, 2019.
- Michael J. Ferracane, Ariana Brice-Tutt, Jay P. McLaughlin and J. V. Aldrich, “The cyclic

- tetrapeptide JVA-4001 demonstrates multifunctional opioid antagonist-agonist activity and prevents reinstatement of drug-seeking behavior in mice,” poster, American Peptide Symposium, Monterey, CA, June 22-27, 2019.
- Solomon A. Gisemba, Thomas F. Murray, and Jane V. Aldrich, “Synthesis of bicyclic snalogs of the kappa opioid receptor antagonist arodyn,” oral presentation, American Peptide Symposium, Monterey, CA, June 22-27, 2019.
- L. E. Hanold and J. V. Aldrich, “Exploring the effects of macrocyclic tetrapeptides with promising anti-proliferative activity in triple negative breast cancer,” poster, American Peptide Symposium, Monterey, CA, June 22-27, 2019.
- R. E. Pescatore, L.E. Hanold, and J.V. Aldrich, “Uncovering the effects of macrocyclic tetrapeptides on the c-Myc degradation Pathway in prostate cancer cells,” poster, American Peptide Symposium, Monterey, CA, June 22-27, 2019.
- Jane V. Aldrich, Shainnel Eans, Sanjeewa Senadheera, and Jay McLaughlin, “The diversity of macrocyclic tetrapeptides: Structure-activity relationship lessons learned for safer analgesics,” invited speaker, 3rd University of Florida Drug Discovery Symposium, Gainesville, FL, April 25-26, 2019.
- Robyn E. Pescatore and Jane V. Aldrich, “Optimizing the anti-proliferative activity of CJ-15,208 in prostate cancer cells,” poster, 3rd University of Florida Drug Discovery Symposium, Gainesville, FL, April 25-26, 2019.
- Jane V. Aldrich and Jay P. McLaughlin, “Developing peptides and peptidomimetics as potential treatments for substance abuse,” invited speaker, American Chemical Society meeting, Orlando, FL, March 31 - April 4, 2019.
- Tanvir Khaliq and Jane V. Aldrich, “Novel macrocyclic tetrapeptide kappa opioid receptor ligands: Cytochrome P450 metabolism and interactions,” poster, American Chemical Society meeting, Orlando, FL, March 31 - April 4, 2019.
- Robyn E. Pescatore and Jane V. Aldrich, “Optimizing the anti-proliferative activity of CJ-15,208 in prostate cancer cells,” poster, American Chemical Society meeting, Orlando, FL, March 31 - April 4, 2019.
- Jane V. Aldrich, Jay P. McLaughlin and Thomas F. Murray, “Lessons learned from *in vivo* screening of novel opioid peptides. Back to the future?,” **plenary** speaker, Royal Australian Chemical Institute Medicinal Chemistry and Chemical Biology 2018 Conference, Brisbane, Australia, November 18-21, 2018.
- Jay P. McLaughlin, Shainnel O. Eans, Ariana Brice-Tutt, Heather M. Stacy, Grant G. Simpson, Jeremy Coleman, Michael Ferracane and Jane V. Aldrich, “Refinement of cyclic tetrapeptide mixed opioid agonist/antagonists as safer analgesics and treatments for opioid addiction,” oral presentation, 5th Annual Society for Personalized Nano-Medicine Symposium, Miami, FL, November 1-2, 2018.
- Grant G. Simpson, Michael Ferracane, Lisa Wilson, Ariana C. Brice, Shainnel O. Eans, Heather M. Stacy, Jay McLaughlin, and Jane V. Aldrich, “Design, synthesis, and *in vivo* pharmacological evaluation of a macrocyclic peptide opioid receptor ligand with picomolar activity,” poster, Macrocycles 2018, 3rd Royal Society of Chemistry BMCS Medicinal Chemistry Symposium on Macrocycles, Stevenage, UK, October 8-9, 2018.
- Jane V. Aldrich, Dmitry Yakovlev, Shainnel O. Eans, Heather M. Stacy, Thomas F. Murray, and

- Jay P. McLaughlin, "Substitution of aromatic residues in the macrocyclic opioid peptide [D-Trp]CJ-15,208 alters the opioid activity profile *in vivo*," oral presentation, European Peptide Symposium, Dublin, Ireland, August 26-31, 2018.
- Jane V. Aldrich, Jay P. McLaughlin and Thomas F. Murray, "Back to the future? Lessons learned from *in vivo* screening of novel opioid peptides," **keynote** speaker, 3rd Asian Conference on Pharmaceutical Sciences, Bali, Indonesia, July 3-4, 2018.
- Lisa Wilson, A Brice, Shainnel O. Eans, Heather M. Stacy, Grant Simpson, Michael Ferracane, Jane V. Aldrich, and Jay P. McLaughlin, "Characterization of JVA 4001, a novel mixed opioid agonist/kappa opioid receptor antagonist that attenuates drug and stress-induced reinstatement of extinguished morphine-conditioned place preference," poster, International Narcotic Research Conference, San Diego, CA, June 11-16, 2018.
- Laura E. Hanold, Shainnel Eans, Heather Stacy, Jay P. McLaughlin, and Jane V. Aldrich, "Derivatization of macrocyclic tetrapeptide kappa opioid receptor antagonists by hydroxyproline esterification," poster, American Chemical Society Florida Annual Meeting and Exhibition (FAME), North Palm Harbor, FL, May 3-5, 2018.
- J. V. Aldrich, C. Reedy, H. M. Stacy, J. M. Medina, S. O. Eans, T. J. Cirano, T. F. Murray and Jay P. McLaughlin, "Ring substitution in the macrocyclic opioid peptide CJ-15,208 alters the opioid activity profile *in vivo*," poster, International Narcotic Research Conference, Chicago, IL, July 9-13, 2017.
- Jane V. Aldrich, Christianna Reedy, Thomas F. Murray and Jay P. McLaughlin, "Sensitivity of the opioid activity profile of CJ-15,208 analogs to ring substitution," oral presentation, American Peptide Symposium, Whistler, British Columbia, June 17-22, 2017.
- Michael Ferracane and Jane Aldrich, "Structure-based design of macrocyclic tetrapeptides intended to modulate the opioid receptors," poster, American Peptide Symposium, Whistler, British Columbia, June 17-22, 2017.
- Laura E. Hanold, Shainnel Eans, Heather Stacy, Jay P. McLaughlin and Jane V. Aldrich, "Derivatization of a macrocyclic tetrapeptide kappa opioid receptor antagonist to improve physiochemical properties, poster, American Peptide Symposium, Whistler, British Columbia, June 17-22, 2017.
- Jane V. Aldrich, Sanjeewa Senadheera, and Jay McLaughlin, "Exploration of new opioid macrocyclic tetrapeptides as potential analgesics," invited oral presentation, Florida Annual Meeting and Exhibition (FAME), American Chemical Society, Palm Harbor, FL, May 4-6, 2017.
- Grant G. Simpson, Michael Ferracane, Nicolette Ross, Jay McLaughlin, and Jane V. Aldrich, "Synthesis and pharmacological evaluation of macrocyclic tetrapeptides as opioid receptor ligands," poster, Florida Annual Meeting and Exhibition (FAME), American Chemical Society, Palm Harbor, FL, May 4-6, 2017.
- Jane V. Aldrich, Sanjeewa Senadheera, Thomas F. Murray, and Jay P. McLaughlin, "Macrocyclic peptides as potential treatments for pain and drug abuse," invited oral presentation, MEDI 4, 253rd American Chemical Society meeting, San Francisco, CA, April 2-6, 2017.

- Michael Ferracane and Jane Aldrich, "Structure-based design of macrocyclic tetrapeptides intended to modulate the opioid receptors," poster, MEDI 441, 253rd American Chemical Society meeting, San Francisco, CA, April 2-6, 2107.
- J. P. McLaughlin, S. O. Eans, J. M. Medina, T. J. Cirino, H. M. Stacy, C. Reedy, T. F. Murray and J. V. Aldrich, "Variable opioid activity arising from ring substitution in CJ-15,208 and characterization of an analog that blocks stress-induced reinstatement of extinguished cocaine-conditioned place preference," oral presentation (JPM), Therapeutic Potential of Kappa Opioids, Philadelphia, PA April 3-6, 2017.
- Jay P. McLaughlin, Shainnel O. Eans, Jessica M. Medina, Kristen A. Hymel, Sanjeewa N. Senadheera, Thomas F. Murray and Jane V. Aldrich, "Delta-opioid Receptor (DOR) Antagonism Introduced by Tryptophan Substitution in CJ-15,208 Prevents Antinociceptive Tolerance and Stress-Induced Reinstatement of Extinguished Drug-conditioned Place Preference," poster, Society for Neuroscience meeting, San Diego, CA, November 12-16, 2016.
- Jane V. Aldrich, Sanjeewa N. Senadheera, Michelle L. Ganno, Shainnel O. Eans, Thomas F. Murray and Jay P. McLaughlin, "Small Changes in Macrocyclic Tetrapeptide Structure have Significant Impact on Opioid Activity *in vivo*," invited oral presentation, College of Problems of Drug Dependence, Palm Springs, CA, June 11-16, 2016.
- Solomon A. Gisemba and Jane V. Aldrich, "Optimization of the Synthesis of Novel Cyclic Peptides using Ring Closing Metathesis and Preparation of Analogs of the Kappa Opioid Receptor Antagonist Arodyn," oral presentation (SAG), 92nd Florida ACS Annual Meeting and Exposition (FAME), Palm Harbor, FL, May 5-7, 2016.
- M.J. Ferracane and J.V. Aldrich, J., "Docking Studies Illuminate a Likely Binding Mode of Noncanonical Opioid Peptides," oral presentation (MF), 45th American Chemical Society Western Regional Meeting, San Marcos, CA, November 6-8, 2015.
- M.J. Ferracane and J.V. Aldrich, J., "Insight into opioid-opioid receptor binding through analysis of crystallographic data, mutagenesis studies, and SAR of opioid peptides" 250th National American Chemical Society Meeting, Boston, MA, August 16-20, 2015.
- M.J. Ferracane and J.V. Aldrich, "Opioid Ligand Binding to Opioid Receptors: Insight and Implications for Peptide Design," oral (Young Investigators presentation by MJF), 24th American Peptide Symposium, Orlando, FL, June 20-26, 2015.
- S.A. Gisemba, W. J. Fang, and J.V. Aldrich, "Peptide Ring Closing Metathesis Reactions: Minimizing Side Reactions in Arodyn Analogs," poster, 24th American Peptide Symposium, Orlando, FL, June 20-26, 2015.
- C. Reedy, A. Mukhopadhyay, S. Senadheera, T. Khaliq, and J. Aldrich, "CJ-15,208 Analogues: Their Permeability Across Biological Barriers and Interaction with P-glycoprotein," poster, 24th American Peptide Symposium, Orlando, FL, June 20-26, 2015.
- S.N. Senadheera and J.V. Aldrich, "Optimized and Improved Method to Generate Synthetically Challenging Macrocyclic Tetrapeptides that do not have a Turn Inducer," poster, 24th American Peptide Symposium, Orlando, FL, June 20-26, 2015.
- T.V. Yakovleva and J.V. Aldrich, "Optimization of a Larger Scale Synthesis of Zyklophin, a Highly Selective Peptide Kappa Opioid Receptor Antagonist," poster, 24th American Peptide Symposium, Orlando, FL, June 20-26, 2015.

- J.V. Aldrich, S.N. Senadheera, T.F. Murray, M.L. Ganno, S.O. Eans, and J.P. McLaughlin, "Analogues of the novel macrocyclic tetrapeptide CJ-15,208 exhibit diverse opioid activity profiles," invited oral presentation, International Narcotic Research Conference, Phoenix, AZ, June 15-19, 2015.
- K.A. Hymel, S.O. Eans, M.L. Ganno, E. Mizrahi, N. Ross, S.N. Senadheera, J.V. Aldrich, J.P. McLaughlin, "A novel mixed-action μ -opioid receptor (MOR) agonist/ δ -opioid receptor (DOR) antagonist prevents stress-induced reinstatement of extinguished cocaine-seeking behavior," poster, International Narcotic Research Conference, Phoenix, AZ, June 15-19, 2015.
- S.O. Eans, M. Ganno, E. Mizrahi, S. Senadheera, J.V. Aldrich, J. P. McLaughlin, "Influence of stereochemistry in the macrocyclic tetrapeptide CJ-15,208 on antinociceptive efficacy and opioid receptor selectivity," poster, College of Problems of Drug Dependence, Phoenix, AZ, June 13-18, 2015.
- J.V. Aldrich, S. N. Senadheera, M. L. Ganno, S.O. Eans and J.P. McLaughlin, "Liability Profiles and Activity in Different Pain Models of Analogues of the Macrocyclic Tetrapeptide CJ-15,208," invited oral presentation, Kappa Therapeutics Conference, Chapel Hill, NC, April 20-24, 2015.
- Jane V. Aldrich, "Orally Active Macrocyclic Peptides as Analgesics and Potential Treatments for Drug Abuse," invited oral presentation, Boulder Peptide Symposium, Boulder, CO, September 22-24, 2014.
- T. Khaliq, S. N. Senadheera, S. M. Lunte and J. V. Aldrich, "Structure-Metabolism Relationships of Novel Macrocyclic Peptide Opioid Receptor Ligands," poster, MEDI 430, 248th American Chemical Society, San Francisco, CA, August 10-14, 2014.
- J.V. Aldrich, S.N. Senadheera, T.F. Murray, M.L. Ganno, S.O. Eans, E. Mizrahi and J.P. McLaughlin, "Characterization of the Antinociceptive and Kappa Opioid Receptor Antagonist Activity of Analogues of the Macrocyclic Tetrapeptide CJ-15,208," poster, International Narcotic Research Conference, Montreal, Canada, July 13-17, 2014.
- Solomon A. Gisemba and Jane V. Aldrich, "Minimizing Side Reactions in Novel Peptide Ring Closing Metathesis Reactions," poster, Chemistry and Biology of Peptides Gordon Research Conference, Ventura, CA, February 23-28, 2014.
- Sanjeewa N. Senadheera and Jane V. Aldrich, "First Successful Synthesis of the All L-Amino Acid Natural Product Macrocyclic Tetrapeptide *cyclo*[Pro-Val-Pro-Tyr]," oral presentation, ORGN 453, 246th American Chemical Society National Meeting, Indianapolis, IN, September 8-12, 2013.
- Sanjeewa N. Senadheera, Shainnel O. Eans, Jay P. McLaughlin, and Jane V. Aldrich, "Optimized and Improved Larger Scale Synthesis of Opioid Macrocyclic Tetrapeptides with Potential for Drug Development," poster, MEDI 274, 246th American Chemical Society National Meeting, Indianapolis, IN, September 8-12, 2013.
- Sanjeewa N. Senadheera, Justin T. Douglas, and Jane V. Aldrich, "Backbone Conformations and Hydrogen Bonding Patterns of Analogues of the Macrocyclic Tetrapeptide CJ-15,208," poster, MEDI 275, 246th American Chemical Society National Meeting, Indianapolis, IN, September 8-12, 2013.

- J. V. Aldrich, S. N. Senadheera, S. Eans, M. L. Ganno, E. Mizrachi, and J. P. McLaughlin, "Diverse Pharmacological Profiles of Novel Peptide Kappa Opioid Receptor Ligands," oral presentation, Kappa Therapeutics 2013, Cambridge, MA, April 24-27, 2013.
- Jane V. Aldrich, Sanjeewa N. Senadadheera, Shainnel O. Eans, Michelle L. Ganno, Nicolette C. Ross, and Jay P. McLaughlin, "Novel Opioid Peptides as Potential Treatments for Pain and Drug Abuse, **invited** oral presentation, Zing Peptide Chemistry conference, Xcaret, Mexico, November 3-6, 2012.
- T.V. Yakovleva and J.V. Aldrich, "Scale Up Synthesis of Zyklophin, a Highly Selective Peptide Kappa Opioid Receptor Antagonist," poster, ORGN 885, 244th American Chemical Society National Meeting, Philadelphia, PA, August 19-23, 2012.
- Sanjeewa N. Senadheera, Shainnel O. Eans, Nicolette C. Ross, Jay P. McLaughlin, and Jane V. Aldrich, "The Synthesis and Purification of Opioid Macrocyclic Tetrapeptides on a Larger Scale for *in vivo* Pharmacological Evaluation," poster, ORGN 886, 244th American Chemical Society National Meeting, Philadelphia, PA, August 19-23, 2012.
- J.V. Aldrich, S.N. Senadheera, K. Patkar, S.O. Eans, and J.P. McLaughlin, "Novel Kappa Opioid Receptor Peptide Ligands as Potential Treatments for Drug Abuse, oral presentation, International Narcotic Research Conference, Kansas City, MO, July 15-20, 2012.
- K.M. DiMattio, T.V. Yakovleva, J.V. Aldrich, L.Y. Liu- Chen, and A. Cowan, "Zyklophin, the Short-acting Kappa Opioid Antagonist, Induces Scratching in Mice," poster, International Narcotic Research Conference, Kansas City, MO, July 15-20, 2012.
- A. Joshi, T. Khaliq, S. Senadheera, A. Mukhopadhyay, S.M. Lunte , and J.V. Aldrich, "Physiochemical and Pharmacokinetic Properties of Novel Macrocyclic Peptide Kappa Opioid Receptor Ligands," poster, International Narcotic Research Conference, Kansas City, MO, July 15-20, 2012.
- S.N. Senadheera, S.O. Eans, N.C. Ross, J.P. McLaughlin, T.F. Murray, and J.V. Aldrich, "Novel Analogs of the Kappa Opioid Receptor Ligand CJ-15,208 with Potential for Drug Development," poster, International Narcotic Research Conference, Kansas City, MO, July 15-20, 2012.
- Jane V. Aldrich, Shainnel O. Eans, Michelle L. Ganno, Sanjeewa N. Senadadheera, Kshitij A. Patkar, and Jay P. McLaughlin, "Central Opioid Activity of Peripherally Administered Novel Kappa Opioid Receptor Peptide Ligands," poster, Barriers of the CNS, Bridging Barriers to Treat CNS Disease, Gordon Research Conference, New London, NH, June 17-22, 2012.
- Jane V. Aldrich, Shainnel O Eans, Michelle L. Ganno, Sanjeewa N, Senadheera, Kshitij A. Patkar, and Jay P. McLaughlin, "Orally Active Cyclic Tetrapeptides as Potential Treatments for Drug Abuse," oral presentation, Behavior, Biology and Chemistry: Translational Research in Addiction, San Antonio, TX, March 3-4, 2012.
- J.V. Aldrich, S.S. Kulkarni, S.N. Senadheera, N.C. Ross, K.J. Reilley, S.O. Eans, M.L. Ganno, and J.P. McLaughlin, "Novel Kappa Opioid Peptides with Drug-Like Properties," oral presentation, 242nd American Chemical Society National Meeting, Denver, CO, August 28 – September 1, 2011.

- A.A. Joshi, T.F. Murray, and J.V. Aldrich, "Structure-Activity Relationships of the Systemically Active Peptide Kappa Opioid Receptor Antagonist Zyklophin," poster, 242nd American Chemical Society National Meeting, Denver, CO, August 28 – September 1, 2011.
- J.V. Aldrich, S.S. Kulkarni, S.N. Senadheera, K.A. Patkar, N.C. Ross, K.J. Reilley, S. Eans, M.L. Ganno, Y. Zhang, M.J. Kreek, and J.P. McLaughlin, "Peptide Kappa Opioid Receptor Ligands: Challenges in Development and Successes," oral presentation, Kappa Therapeutics: Therapeutic Potential of Kappa Opioids in Pain and Addiction, Seattle, WA, July 10-13, 2011.
- L.-Y. Liu-Chen, J. V. Aldrich, T. Yakovleva, and P. Huang, "Zyklophin, a Systemically Active Selective Peptide KOPR Antagonist with Short Duration of Action, has Anxiolytic-like Effects in Mice," poster, Kappa Therapeutics: Therapeutic Potential of Kappa Opioids in Pain and Addiction, Seattle, WA, July 10-13, 2011.
- J.V. Aldrich, S.S. Kulkarni, S.N. Senadheera, N.C. Ross, K.J. Reilley, S.O. Eans, M.L. Ganno, J.P. McLaughlin, "Orally Active Opioid Peptides as Leads for Drug Development," poster, 22nd American Peptide Symposium, San Diego, CA, June 25-30, 2011.
- Anand A. Joshi, Thomas F. Murray, and Jane V. Aldrich, "Structure-Activity Relationships of Dynorphin A Analogs Targeting Kappa Opioid Receptors," poster, 22nd American Peptide Symposium, San Diego, CA, June 25-30, 2011.
- Sanjeeva N. Senadheera, Santosh Kulkarni, Jay P. McLaughlin, Jane V. Aldrich, Improved Synthesis of CJ-15,208 Isomers and Their Pharmacological Activity at Opioid Receptors," poster, 22nd American Peptide Symposium, San Diego, CA, June 25-30, 2011.
- J.V. Aldrich, S.S. Kulkarni, S.N. Senadheera, N.C. Ross, K.J. Reilley, S. Eans, M.L. Ganno, T.F. Murray, and J.P. McLaughlin, "Unexpected Opioid Activity Profiles of Analogs of the Novel Peptide Kappa Opioid Receptor Ligand CJ-15,208," poster, International Narcotic Research Conference, Hollywood, FL, June 21-25, 2011.
- S.O. Eans, M.L. Ganno, J.V. Aldrich, and J.P. McLaughlin, "Oral activity of cyclic tetrapeptide JVA-2802: short-acting KOR antagonism and prevention of stress-induced reinstatement of cocaine-CPP," poster, International Narcotic Research Conference, Hollywood, FL, June 21-25, 2011.
- N.C. Ross, S. Kulkarni, J. V. Aldrich and J. P. McLaughlin, "Oral availability of CJ-15,208, an opioid mixed agonist/antagonist analgesic with fewer liabilities *in vivo*," poster, International Narcotic Research Conference, Hollywood, FL, June 21-25, 2011.
- J.V. Aldrich, S.S. Kulkarni, S.N. Senadheera, N.C. Ross, K.J. Reilley, S.O. Eans, M.L. Ganno, and J.P. McLaughlin, "Novel Opioid Peptides with Drug-like Properties as Potential Analgesics," invited oral presentation, Central Regional American Chemical Society meeting, Indianapolis, IN, June 8-10, 2011.
- J.V. Aldrich, J.P. McLaughlin, and T.F. Murray, Development of Systemically Active Peptides and Potential for Drug Development, **invited** oral presentation, 5th International Peptide Symposium, Kyoto, Japan, December 4-9, 2010.
- Kshitij A. Patkar, Kendra Dresner, and Jane V. Aldrich, "Metabolic Stability of Structurally Modified Aroclor Analogs in Biological Matrices," poster, International Narcotic Research Conference, Malmo, Sweden, July 11-16, 2010.

- Yong Zhang, Kshitij A. Patkar, Eduardo Butelman, Ann Ho, Jane V. Aldrich, and Mary Jeanne Kreek, "Effect of Zyklophin, a Dynorphin Analog, on Mouse Striatal Dopamine Levels," poster, International Narcotic Research Conference, Malmo, Sweden, July 11-16, 2010.
- Jane V. Aldrich, "Peptide Kappa Opioid Receptor Ligands – Potential for Drug Development," **invited** oral presentation, College on Problems of Drug Dependence, Scottsdale, AZ, June 13-17, 2010.
- J. V. Aldrich, N. C. Ross, S. S. Kulkarni, J. P. McLaughlin, and T. F. Murray, "Novel Cyclic Tetrapeptides as Kappa Opioid Receptor Ligands," oral presentation, 8th Australian Peptide Conference, South Stradbroke Island, Queensland, Australia, October 11-16, 2009.
- J. V. Aldrich, K. A. Patkar, K. Dresner, and S. M. Lunte, "Design, Synthesis and Evaluation of Metabolically Stable Peptide Kappa Opioid Receptor Antagonists," **invited** oral presentation, 2nd International Modern Solid Phase Peptide Synthesis and Its Applications Symposium, Gold Coast, Queensland, Australia, October 8-11, 2009.
- W. J. Hartsock, M. Del Borgo, D. S. Moore, and J. V. Aldrich, "The Design and Synthesis of a Novel Multifunctional Peptide to Study Delta Opioid Receptors," oral presentation, 2nd International Modern Solid Phase Peptide Synthesis and Its Applications Symposium, Gold Coast, Queensland, Australia, October 8-11, 2009.
- J. V. Aldrich, J. P. McLaughlin, K. A. Patkar, and S. M. Lunte, "Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development," **invited** oral presentation, International Narcotic Research Conference, Portland, OR, July 12-16, 2009.
- K. A. Patkar, K. Dresner, S. M. Lunte, and J. V. Aldrich, "Metabolism of Kappa Opioid Receptor (KOR) Peptides in Rat Brain and Identification of Stable Peptide KOR Antagonists," poster presentation, International Narcotic Research Conference, Portland, OR, July 12-16, 2009.
- N. C. Ross, S. S. Kulkarni, J. P. McLaughlin, T. F. Murray, and J. V. Aldrich, "Novel Cyclic Tetrapeptides as Kappa Opioid Receptor Ligands," poster presentation, International Narcotic Research Conference, Portland, OR, July 12-16, 2009.
- W. J. Hartsock, M. Del Borgo, D. S. Moore, and J. V. Aldrich, "The Design and Synthesis of a Novel Multifunctional Peptide to Study Delta Opioid Receptors," submitted poster, 21st American Peptide Symposium, Bloomington, IN, June 7-12, 2009.
- J. V. Aldrich, K. A. Patkar, J. P. McLaughlin, and S. M. Lunte, "Identification of a Systemically Active Peptidic Kappa Opioid Receptor Antagonist and Its Potential Applications," **invited** oral presentation, Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat Springs, CO, January 25-29, 2009.
- J. V. Aldrich, S. S. Kulkarni, N. C. Ross, T. F. Murray, and J. P. McLaughlin, "A Novel Tetrapeptide with Analgesic Activity at Opioid Receptors," **invited** oral presentation, Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat Springs, CO, January 25-29, 2009.
- J. Anand and J. V. Aldrich, "Analogues of Dynorphin B to Study Kappa Opioid Receptor Ligand Interactions," submitted poster, Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat Springs, CO, January 25-29, 2009.
- W. J. Hartsock, M. Del Borgo, D. S. Moore, and J. V. Aldrich, "The Design and Synthesis of a Novel Multifunctional Peptidic Ligand to Study Delta Opioid Receptors," submitted

- poster, Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat Springs, CO, January 25-29, 2009.
- K. M. Prevatt-Smith, K. A. Patkar, and J. V. Aldrich, "Metabolic Stability of the Highly Selective, Dynorphin A-based Kappa Opioid Receptor Antagonist Zyklophin," submitted poster, Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat Springs, CO, January 25-29, 2009.
- N. C. Ross, S. S. Kulkarni, J. P. McLaughlin, T. F. Murray, and J. V. Aldrich, "Novel Peptide Lignads as Kappa Opioid Receptor Antagonists," submitted poster, Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat Springs, CO, January 25-29, 2009.
- B. Sinha, M. Del Borgo, T. F. Murray and J. V. Aldrich, "Multifunctional Affinity Label Derivatives of Dermorphin for Mu Opioid Receptors," submitted poster, Winter Conference on Medicinal and Bioorganic Chemistry, Steamboat Springs, CO, January 25-29, 2009.
- K. A. Patkar, K. M. Prevatt, S. M. Lunte, J. P. McLaughlin and J. V. Aldrich, "Metabolism of Arodyn and Zyklophin in Rat Brain and Blood: Toward the Development of Kappa Opioid Receptor (KOR) Antagonists for the Treatment of Cocaine Addiction," American Association of Pharmaceutical Scientists annual meeting, Atlanta, GA, November 16-20, 2008.
- J. V. Aldrich, K. A. Patkar, J. P. McLaughlin and S. M. Lunte, "Identification of a Systemically Active Peptide Kappa Opioid Receptor Antagonist," submitted poster, International Narcotic Research Conference, Charleston, SC, July 13-18, 2008.
- N. C. Ross, S. S. Kulkarni, J. P. McLaughlin, T. F. Murray, and J. V. Aldrich, "Novel Cyclic Tetrapeptides as Kappa Opioid Receptor Antagonists," submitted poster, International Narcotic Research Conference, Charleston, SC, July 13-18, 2008.
- B. Dattachowdhury, T. F. Murray, and J. V. Aldrich, "The Discovery of Dermorphin-Based Affinity Labels with High Affinity for Mu Opioid Receptors (MOR)," submitted poster, International Narcotic Research Conference, Charleston, SC, July 13-18, 2008.
- Jane V. Aldrich, "Design and Synthesis of Peptide Ligands for Kappa Opioid Receptors," **invited** oral presentation, Peptide Users Group meeting, Mimotopes, Inc., Melbourne, Australia, October 30, 2007.
- Jane V. Aldrich, Kshitij A. Patkar, Arvind Chappa, Kenneth L. Audus, Susan M. Lunte, and Jay P. McLaughlin, "Development of Centrally Acting Peptide Analogs: Structure-Transport Studies and Pharmacological Evaluation of Analogs of the Opioid Peptide Dynorphin A," oral presentation, International Peptide Symposium, Cairns, Queensland, Australia, October 21-25, 2007.
- Jane V. Aldrich, Xin Wang, Angie Peck, Bhaswati Dattachowdhury, Thomas F. Murray, Vivek Kumar, and Jia Bei Wang: "Solid Phase Synthesis and Application of Labeled Peptide Derivatives: Probes of Receptor-Ligand Interactions," **invited** oral presentation, Modern Solid Phase Peptide Synthesis meeting, Port Douglas, Queensland, Australia, October 17-20, 2007.
- Jane V. Aldrich, Kshitij A. Patkar, Jay P. McLaughlin, and Susan M. Lunte, "Identification of a Systemically Active Peptidic Kappa Opioid Receptor Antagonist," **invited** oral

- presentation, Western Regional American Chemical Society Meeting, San Diego, CA, October 10-12, 2007.
- B. Dattachowdhury, T. F. Murray, and J. V. Aldrich, "The Synthesis of DAMGO-Based Potential Affinity Labels with High Mu Opioid Receptor Affinity and the Formation of Cyclic O-Thiocarbamates," submitted poster, American Peptide Symposium, Montreal, Quebec, June 26-30, 2007.
- W.-J. Fang, T.F. Murray, and J. V. Aldrich, "Design, Synthesis and Biological Activities of Cyclic Aroclon Analogues by Ring-Closing Metathesis (RCM)," submitted poster, American Peptide Symposium, Montreal, Quebec, June 26-30, 2007.
- Santosh S. Kulkarni, Nicolette C. Ross, Jay P. McLaughlin, Thomas F. Murray and Jane V. Aldrich, "Synthesis of Cyclic Tetrapeptide CJ 15, 208: A Novel Kappa Opioid Receptor Antagonist," submitted poster, American Peptide Symposium, Montreal, Quebec, June 26-30, 2007.
- A. K. Chappa, J. V. Aldrich, K. Audus and S. M. Lunte, "Evaluation of Metabolic Stability, Plasma Protein Binding, Blood-Brain Barrier Permeability and Pharmacokinetic Properties of Dynorphin Analogs," submitted poster, Globalization of Pharmaceuticals Education Network (GPEN) meeting, Lawrence, KS, October 25-27, 2006.
- J. V. Aldrich, J. P. McLaughlin, C. Shay, Z. Weinstein, A. K. Chappa, S. M. Lunte and M. A. Bennett, "Unusual Pharmacological Profile of the Peptide κ Opioid Receptor Antagonist Aroclon," submitted poster, International Narcotic Research Conference, St. Paul, MN, July 9-14, 2006.
- Jane V. Aldrich, Jay P. McLaughlin, Arvind K. Chappa, Susan M. Lunte and Marco A. Bennett, "Unusual Pharmacological Profile of the Peptide Kappa Opioid Receptor Antagonist Aroclon," oral presentation, Pain Interest Group meeting, Iowa City, IA, May 19, 2006.
- Wei-Jie Fang, Marco A. Bennett, Thomas F. Murray, and Jane V. Aldrich, "Identification and Structure-Activity Relationships of Aroclon Analogs Exhibiting Inverse Agonist Activity at Kappa Opioid Receptors," Chemistry and Biology of Peptides Gordon Research Conference, Ventura, CA, February 19-23, 2006.
- Arvind K. Chappa, Kenneth L. Audus, Jane V. Aldrich, and Susan M. Lunte, "Quantitative Determination of Dynorphin-A Analogs in Rat Plasma using LC-MS/MS," American Association of Pharmaceutical Scientists, November 2005.
- Arvind K. Chappa, Kenneth L. Audus, Jane V. Aldrich, and Susan M. Lunte, "Evaluation of the Metabolic Stability and Blood Brain Barrier Permeability of Dynorphin-A Analogs," American Association of Pharmaceutical Scientists, November 2005.
- Wei-Jie. Fang, Marco A. Bennett, Thomas F. Murray and Jane V. Aldrich, "An Unexpected Side Reaction Involving the Deletion of an Acetylated N-Methyl-Amino Acid from the N-Terminus of Peptides," submitted poster, American Peptide Symposium, San Diego, CA, June 18-23, 2005.
- A. M. Peck, V. Kumar, T. F. Murray, and J. V. Aldrich, "Synthesis and Pharmacological Evaluation of Dual Labeled Delta Opioid Receptor Peptides," submitted poster, American Peptide Symposium, San Diego, CA, June 18-23, 2005.

- S. C. Vigil-Cruz, A. M. Peck, and J. V. Aldrich, "Evaluation of Solid Supports and Solvent Conditions for Use with Microwave-Assisted Solid-Phase Peptide Synthesis," submitted poster, American Peptide Symposium, San Diego, CA, June 18-23, 2005.
- X. Wang, T. F. Murray, and J. V. Aldrich, "Synthesis and Pharmacological Evaluation of a New Generation of TIPP-Derived Dual-Labeled Ligands for Delta Opioid Receptors," submitted poster American Peptide Symposium, San Diego, CA, June 18-23, 2005.
- Jane V. Aldrich, Sandra C. Vigil-Cruz, and Angela Peck, "Microwave-Assisted Solid Phase Peptide Synthesis," **invited** oral presentation, 3rd International Microwaves in Chemistry Conference, Orlando, FL, March 3-6 2005.
- Jane V. Aldrich, Marco A. Bennett, and Thomas F. Murray, "Synthesis and Pharmacological Evaluation of a Focused Combinatorial Library based on the Kappa Opioid Receptor Antagonist Aroclon (Ac[Phe^{1,2,3},Arg⁴,D-Ala⁸]dynorphin A-(1-11)NH₂," submitted poster presentation, AAPS-NIDA Symposium Frontiers in Science: Drug Addiction – From Basic Research to Therapies, Bethesda, MD, September 9-11, 2004.
- Z. Marinova, V. Vukojevic, S. Surcheva, T. Yakovleva, G. Cebers, L. Hugonin, W. Fang, J. V. Aldrich, A. Gräslund, L. Terenius, and G. Bakalkin, "Internalization of Dynorphins into Cells and Their Accumulation in the Cytoplasm," International Narcotic Research Conferences, Kyoto, Japan, July 18-23, 2004.
- Jane V. Aldrich, "Peptide Ligands as Probes for Opioid Receptors," **invited** oral presentation, College on Problems of Drug Dependence 66th annual meeting, San Juan, Puerto Rico, June 12-17, 2004.
- Jane V. Aldrich, "A Tale of Two Labels: the Design and Synthesis of Dual Labeled Peptides as Pharmacological Tools," **invited** oral presentation, Chemistry and Biology of Peptides Gordon Research Conference, Ventura, CA, February 15-20, 2004.
- J. V. Aldrich, V. Kumar, J. B. Wang, and T. F. Murray, "Dual Labeled Derivatives of TIPP as Tools to Study Delta Opioid Receptors," submitted poster, International Narcotic Research Conference, Perpignan, France, July 6-11, 2003.
- M.W. Leighty, T.F. Murray, and J.V. Aldrich, "Structure-Activity Relationships of a Novel Cyclic Dynorphin A Analog with Kappa Opioid Receptor Antagonist Activity," submitted poster, 18th American Peptide Symposium, Boston, MA, July 18-24, 2003.
- M. Leighty, T. F. Murray, and J. V. Aldrich, "Conformational Analysis of Cyclic Peptide Analogs of the Opioid Peptide Dynorphin A," submitted poster, Midwest Regional meeting, American Chemical Society, Lawrence, KS, October 23-25, 2002
- M. A. Bennett, T. F. Murray, and J. V. Aldrich, "Design, Synthesis and Opioid Activity of Analogs of Aroclon, A Novel Kappa-Selective Antagonist " submitted poster, INRC, Asilomar, CA July 9-14, 2002.
- M. A. Bennett, T. F. Murray, and J. V. Aldrich, " Design, Synthesis and Opioid Activity of Analogs of Aroclon, A Novel Kappa-Selective Antagonist," submitted poster, FASEB, New Orleans, March, 2002.
- B. Vig, T. F. Murray, and J. V. Aldrich, "Synthesis of Novel N-Terminal Cyclic Dynorphin A Analogues: Strategies and Side Reactions," oral presentation, Young Investigators Symposium, 17th American Peptide Symposium/ 2nd International Peptide Symposium, San Diego, June, 2001.

- M. A. Bennett, T. F. Murray, and J. V. Aldrich, "Structure-Activity Relationship Studies of Aroclor, A Novel Dynorphin A-(1-11) Analog," submitted poster, 17th American Peptide Symposium/ 2nd International Peptide Symposium, San Diego, June, 2001.
- K. Patkar, T. F. Murray and J.V. Aldrich, "Design and Synthesis of [N-benzylTyr¹]Dyn A-(1-11) Analogs with C-terminal Modification and Evaluation of Their Opioid Activity," submitted poster, 17th American Peptide Symposium/ 2nd International Peptide Symposium, San Diego, June, 2001.
- C. Sasiela, M. A. Bennett, T. F. Murray and J. V. Aldrich, "C-Terminal Structure-Activity Relationships for the Novel Opioid Peptide JVA-901 (Venorphin)," submitted poster, 17th American Peptide Symposium/ 2nd International Peptide Symposium, San Diego, June, 2001.
- J. Aldrich, H. Choi and V. Kumar, "Novel Peptide-Based Affinity Labels: The Design and Solid Phase Synthesis of Opioid Peptide Analogues Using Diverse Protection Strategies," **invited** oral presentation, 221st American Chemical Society meeting, San Diego, CA, April 1-5, 2001.
- J. Aldrich, Q. Wan, and T. Murray, "Identification of Novel Kappa Opioid Receptor Selective Peptides from a Combinatorial Library," submitted poster, PacificChem, Honolulu, HA, December 14-19, 2000.
- B. Vig, J. V. Aldrich and T. F. Murray, "Effect of Substitutions in the "Message" Sequence on the Opioid Activity of Cyclic Dynorphin A Analogs," submitted poster, MEDI 232, 220th American Chemical Society meeting, Washington, D.C., August 20-24, 2000.
- V. Kumar, T. F. Murray and J. V. Aldrich, "Solid-phase Synthesis and Pharmacological Evaluation of Labeled TIP(P) Analogs," submitted poster, MEDI 237, 220th American Chemical Society meeting, Washington, D.C., August 20-24, 2000.
- V. Kumar and J. V. Aldrich, "Unexpected Fmoc Deprotection Under Alloc Deprotection Conditions During Solid-phase Synthesis," submitted poster, Organic Chemistry Division, 220th American Chemical Society meeting, Washington, D.C., August 20-24, 2000.
- L. Charoenchai, H. Y. Wang, J. B. Wang, and J. V. Aldrich, "Synthesis and Pharmacological Activity of Orphanin FQ(1-13)NH₂," submitted poster, MEDI 238, 220th American Chemical Society meeting, Washington, D.C., August 20-24, 2000.
- A. Coop, D. Y. Maeda, W. Guang, K. C. Rice, J. V. Aldrich, and J.-B. Wang, "Piperidines and Piperazines as ORL1 Receptor Ligands," submitted poster, 62nd Meeting of the College on Problems of Drug Dependence, San Juan, Puerto Rico, June, 2000.
- J. V. Aldrich, Q. Wan, C. Sasiela, M. Bennett and T. F. Murray, "Novel Kappa Opioid Peptides with Unusual Structure-Activity Relationships," **invited** oral presentation, Rational Design of Agents" symposium, 32nd American Chemical Society Central Regional Meeting, Covington, KY, May 16-19, 2000.
- V. Kumar, T. F. Murray, and J. V. Aldrich, "Synthesis and Biological Activity of Extended TIPP (Tyr-Tic-Phe-Phe) Analogues," submitted poster, 218th American Chemical Society meeting, New Orleans, LA, August 22-26, 1999. *Abst. Papers Am. Chem. Soc.* **1999**, 218, U1006.

- B. Vig, T. F. Murray, and J. V. Aldrich, "Synthesis and Pharmacological Evaluation of Analogues *cyclo*[D-Asp²,Dap⁵]dynorphin A-(1-11)NH₂ substituted in Positions 1, 3, and 4," submitted oral presentation (B. Vig presenter), Sydney Archer Memorial Symposium on Medicinal Chemistry of Opiates, International Narcotic Research Conference, Sarasota Springs, N.Y., July 10-15, 1999.
- J. V. Aldrich, Q. Wan, and T. F. Murray, "Novel Opioid Peptides as Kappa Opioid Receptor Antagonists," submitted oral presentation, 16th American Peptide Symposium, Minneapolis, MN, June 26 - July 1, 1999.
- H. Choi, T. F. Murray, and J. V. Aldrich, "Synthesis and Evaluation of Potential Affinity Labels for Opioid Receptors," oral presentation (H. Choi presenter), Young Investigators Minisymposium, 16th American Peptide Symposium, Minneapolis, MN, June 26 - July 1, 1999.
- L. Charoenchai, J. B. Wang and J. V. Aldrich, "Design, Synthesis and Evaluation of Orphanin FQ(1-13)NH₂ Analogues," submitted poster, 16th American Peptide Symposium, Minneapolis, MN, June 26 - July 1, 1999.
- B. Vig, H. Choi, and J. V. Aldrich, "New Strategies for the Synthesis of Cyclic Dynorphin A Analogues," submitted poster, 16th American Peptide Symposium, Minneapolis, MN, June 26 - July 1, 1999.
- B. S. Vig, Q. Zheng, T. F. Murray, and J. V. Aldrich, "Dynorphin A Analogs Containing Phenylalanine Analogs in Position 4," submitted poster, 216th American Chemical Society meeting, Boston, MA, August 23-27, 1998, MEDI 288. *Abstr. Papers Am. Chem. Soc.* **1998**, 216, 288-MEDI, Part 2.
- H. Choi, T. F. Murray, and J. V. Aldrich, "Synthesis and Evaluation of Amphibian Opioid Peptide-based Affinity Labels," submitted poster, 216th American Chemical Society meeting, Boston, MA, August 23-27, 1998, MEDI 289. *Abstr. Papers Am. Chem. Soc.* **1998**, 216, 289-MEDI, Part 2.
- Q. Wan, T. F. Murray, and J. V. Aldrich, "Analogues of a Novel Opioid Peptide with Affinity for κ Opioid Receptors," submitted poster, 216th American Chemical Society meeting, Boston, MA, August 23-27, 1998, MEDI 290. *Abstr. Papers Am. Chem. Soc.* **1998**, 216, 290-MEDI, Part 2.
- D. Y. Maeda, F. Berman, T. F. Murray, and J. V. Aldrich, "Synthesis and Evaluation of Affinity Labels Based on the \square Opioid Antagonist, TIPP," submitted poster, 216th American Chemical Society meeting, Boston, MA, August 23-27, 1998, MEDI 291. *Abstr. Papers Am. Chem. Soc.* **1998**, 216, 291-MEDI, Part 2.
- L. Charoenchai, H. Choi, T. F. Murray, and J. V. Aldrich, "Structure-Activity Relationships of a Novel Dynorphin Analog," submitted poster, 216th American Chemical Society meeting, Boston, MA, August 23-27, 1998, MEDI 292. *Abstr. Papers Am. Chem. Soc.* **1998**, 216, 292-MEDI, Part 2.
- J. V. Aldrich, D. Y. Maeda, F. Berman, T. F. Murray, "Synthesis and Evaluation of Affinity Labels Based on the δ Opioid Antagonist, TIPP," submitted poster, 29th International Narcotic Research Conference, Garmisch-Partenkirchen, Germany, July 20-25, 1998.

- Sandra C. Vigil-Cruz and Jane V. Aldrich, "Unexpected Aspartimide Formation During Coupling Reactions Using Asp(OAl) in Solid Phase Peptide Synthesis," submitted poster, 15th American Peptide Symposium, Nashville, TN, June 14-19, 1997.
- Qiang Wan, Jai Bei Wang, and Jane Aldrich, "A Combinatorial Library Study of the "Message" Sequence of Extacet, a Dynorphin A Analogue," submitted poster, 15th American Peptide Symposium, Nashville, TN, June 14-19, 1997.
- Qiang Wan, Jai Bei Wang, and Jane Aldrich, "A Combinatorial Library Study of the "Message" Sequence of Extacet, a Dynorphin A Analogue," submitted oral presentation (Qiang Wan presenter), 31st Middle Atlantic Regional Meeting of the American Chemical Society, Pleasantville, NY, May 27-30, 1997.
- Jane V. Aldrich, Qi Zheng, Beth Olenchek, and Thomas F. Murray, "Design, Synthesis and Pharmacological Evaluation of Dynorphin A Analogues Containing Conformational Constraint of Tyr¹ or Phe⁴," submitted poster, International Narcotic Research Conference, Long Beach, CA, July 21-26, 1996.
- Qi Zheng, Beth Olenchek, Thomas F. Murray, and Jane V. Aldrich, "Design, Synthesis and Pharmacological Evaluation of Dynorphin A Analogues Containing Conformational Constraint of Tyr¹ or Phe⁴," submitted poster, 25th National Medicinal Chemistry Symposium, University of Michigan, Ann Arbor, MI, June 18-22, 1996.
- K. Soderstrom, H. Choi, J. V. Aldrich, and T. F. Murray, "N-Terminal Alkylated Derivatives of [D-Pro¹⁰]Dynorphin A-(1-11) are High Affinity Partial κ -Opioid Receptor Agonists," submitted poster, Society for Neuroscience, San Diego, November, 1995.
- Jane V. Aldrich, Leena Leelasvatanakij, and Dean Y. Maeda, "Synthetic Strategies for the Preparation of Peptide-Based Affinity Labels," submitted oral presentation, 14th American Peptide Symposium, Columbus, OH, June 18-23, 1995.
- Dean Y. Maeda, Thomas F. Murray, and Jane V. Aldrich, "Synthesis of Affinity Labels Based on the Delta Opioid Antagonist, TIPP," submitted poster, 14th American Peptide Symposium, Columbus, OH, June 18-23, 1995.
- Leena Leelasvatanakij and Jane V. Aldrich, "Solid Phase Synthetic Strategies for the Preparation of Affinity Label Analogues of Dynorphin A(1-11)NH₂," submitted poster, 14th American Peptide Symposium, Columbus, OH, June 18-23, 1995.
- Sandhya N. Kulkarni, Heekyung Choi, Thomas F. Murray, Gary E. DeLander, and Jane V. Aldrich, "The Use of the Message-Address Concept in the Design of Potential Antagonists Based on Dynorphin A," submitted poster, 14th American Peptide Symposium, Columbus, OH, June 18-23, 1995.
- O. N. Jensen, S. Kulkarni, J. V. Aldrich, S. E. Bennett, D. W. Mosbaugh, and D. F. Barofsky, "MALDI and ESI MS of Covalent Peptide-Oligonucleotide Hybrids," submitted oral presentation (Ole Jensen presenter), 43rd ASMS Conference on Mass Spectrometry and Allied Topics, Atlanta, GA, May 21-26, 1995.
- S. Arttamangkul and J. V. Aldrich, "A Comparison of Uronium Reagents for Side-chain to Side-chain Cyclization of an Opioid Peptide Analog on a Solid Phase Resin," submitted poster, 23rd European Peptide Symposium, Braga, Portugal, September 4-10, 1994.
- Dean Y. Maeda, Thomas F. Murray, and J. V. Aldrich, "Synthesis of Enkephalin-based Affinity Labels for Delta Opioid Receptors," invited oral presentation (Dean Maeda presenter),

- 208th American Chemical Society National meeting, Washington, D.C., August 21-26, 1994, MEDI 12. *Abstr. Papers Am. Chem. Soc.* **1994**, 208, 12.
- Dean Y. Maeda, Thomas F. Murray, and J. V. Aldrich, "Synthesis of Enkephalin-based Affinity Labels for Delta Opioid Receptors," submitted oral presentation (Dean Maeda presenter), International Narcotic Research Conference, North Falmouth, Massachusetts, July 16-21, 1994.
- S. Arttamangkul, T. F. Murray, G. E. DeLander, W. C. Johnson, and J. V. Aldrich, "Synthesis and Opioid Activity of Conformationally Constrained Dynorphin A Analogues," submitted poster, International Narcotic Research Conference, North Falmouth, Massachusetts, July 16-21, 1994.
- S. Arttamangkul and J. V. Aldrich, "The Synthesis of cyclo[D-Asp²,Dap⁵]Dynorphin A(1-13)NH₂: A Comparison Study of Reagents for Side-Chain to Side-Chain Cyclization on a Solid Phase Resin," submitted poster, 13th American Peptide Symposium, Edmonton, Alberta, Canada, June 20-25, 1993.
- S. Arttamangkul, D. Y. Maeda, W. C. Johnson, and J. V. Aldrich, "Conformational Studies of Cyclic 2,5 Dynorphin A(1-13)NH₂ Analogues," submitted poster, 13th American Peptide Symposium, Edmonton, Alberta, Canada, June 20-25, 1993.
- L. Leelasvatanakij, S. Arttamangkul and J. V. Aldrich, "Comparison of Chromatographic Conditions for Separations of Cyclic Dynorphin A Analogues from Linear Byproducts," submitted poster, 13th American Peptide Symposium, Edmonton, Alberta, Canada, June 20-25, 1993.
- Jane V. Aldrich, Sandra C. Story, Heekyung Choi, Seksiri Arttamangkul, Kristin R. Snyder, Thomas F. Murray, and Gary E. DeLander, "Structure-Activity Relationships of Dynorphin A Analogues Containing Modifications in the "Message" Sequence," **invited** speaker, Alfred Burger Award Symposium, 203rd American Chemical Society National Meeting, San Francisco, CA, April 5-10, 1992, MEDI 204. *Abstr. Papers Am. Chem. Soc.* **1992**, 203, 204.
- Seksiri Arttamangkul, Thomas F. Murray, and Jane V. Aldrich, "Synthesis and Opioid Activity of Conformationally Constrained Dynorphin A Analogs," submitted poster, 203rd American Chemical Society National Meeting, San Francisco, CA, April 5-10, 1992, MEDI 74. *Abstr. Papers Am. Chem. Soc.* **1992**, 203, 74.
- Heekyung Choi, Gary E. DeLander, Thomas F. Murray, and Jane V. Aldrich, "Synthesis and Opioid Activity of [D-Pro¹⁰]Dynorphin A-(1-11) Analogs with N-Terminal Alkyl Substitution," submitted poster, 203rd American Chemical Society National Meeting, San Francisco, CA, April 5-10, 1992, MEDI 73. *Abstr. Papers Am. Chem. Soc.* **1992**, 203, 73.
- Kristin R. Snyder, Thomas F. Murray, and Jane V. Aldrich, "Synthesis and Opioid Activity of Dynorphin A Analogs Containing cis- and trans-4-Aminocyclohexanecarboxylic Acid in the Message Sequence," submitted poster, 203rd American Chemical Society National Meeting, San Francisco, CA, April 5-10, 1992, MEDI 72. *Abstr. Papers Am. Chem. Soc.* **1992**, 203, 72.
- Heekyung Choi, Gary E. DeLander, Thomas F. Murray, Sonia Anderson, and Jane V. Aldrich, "Synthesis and Opioid Activity of Dynorphin A-(1-13) Analogues Substituted at

- Positions 2 and 4," submitted poster, 12th American Peptide Symposium, Cambridge, MA, June 16-21, 1991.
- Sandra C. Story, Mia E. Heidt, Gary E. DeLander, Thomas F. Murray and Jane V. Aldrich, "Synthesis and Opioid Activity of Lys(Ac)⁶- and Lys(Ac)⁹- Dynorphin A-(1-13) Amide", submitted poster, 22nd National Medicinal Chemistry Symposium, Austin, TX, July 29-August 2, 1990.
- Jane V. Aldrich and Sandra C. Story, "Solid Phase Synthetic Strategies for the Preparation of Affinity Labels Derived from Dynorphin A," submitted poster, International Narcotic Research Conference, Noordwijkerhout, the Netherlands, July 8-13, 1990.
- Sandra C. Story and Jane V. Aldrich, "Synthesis of Protected Peptide Amides: Comparison of Resins for Solid Phase Peptide Synthesis," submitted poster, Gordon Research Conference on the Chemistry and Biology of Peptides, Ventura, CA, February 4-9, 1990.
- S. C. Story, G. E. DeLander, T. F. Murray, and J. Aldrich Lovett*, "Synthesis and Opioid Activity of 2-Substituted Analogues of the Opioid Peptide Dynorphin A-(1-13) Amide," submitted poster, 11th American Peptide Symposium, San Diego, CA, July 9-14, 1989.
- Jane Aldrich Lovett*, "Opioid Peptide Analogues to Study Opioid Receptors," **invited** lecture, Dimensions in Bioresearch, Milligen/Biosearch Fall Symposium Series, Seattle, WA, October 28, 1988.
- Jane Aldrich Lovett and Philip S. Portoghese, "δ Opioid Receptor Antagonism of a Series of N,N Dialkyl Leucine Enkephalins," submitted poster, American Chemical Society meeting, Anaheim, CA, September 7-12, 1986, *MEDI 73. Abstr. Papers Am. Chem. Soc. 1986, 192, 73.*
- Jane Aldrich Lovett and Philip S. Portoghese, "Melfalan-Containing N,N-Dialkyl-enkephalin Analogs as Potential Irreversible Antagonists of the δ Opioid Receptor," submitted poster, International Narcotic Research Conference, San Francisco, CA, July 6-11, 1986.
- Jane Aldrich Lovett, Michael V. Darby, and Raymond E. Counsell, "Synthesis and Evaluation of a 19-Aza Analog of Androstenedione as a Potential Aromatase Inhibitor," submitted poster, Conference on Aromatase: New Perspectives for Breast Cancer, Key Biscayne, FL, December 6-9, 1981.

D. Invited lectures, etc. (1996 - present):

- "Novel Opioid Peptides that Don't Follow the Rules," Philip S. Portoghese Lecture, University of Minnesota, Department of Medicinal Chemistry, April 22, 2022.
- "Novel Peptides with Activity in Prostate Cancer," Florida-California NCI U54 CaRE2 Webinar, April 29, 2020.
- "Novel Opioid Peptides that Don't Follow the Rules," Department of Pharmaceutical Sciences, University of Pittsburgh, March 3, 2020.
- "Novel Peptides with Activity in Prostate Cancer," Topics in Cancer Seminar, University of Florida Health Cancer Center, Gainesville, FL, January 31, 2020.

* Former name

- “In vivo Screening of Opioid Peptides: Novel Peptides that Don’t Follow the Rules,” Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, June 7, 2019.
- “The Diversity of Macrocyclic Tetrapeptides: Structure-Activity Relationship Lessons Learned for Safer Analgesics,” UF Drug Discovery Symposium, University of Florida, April 26, 2019.
- “Diverse Peptide Ligands for Kappa Opioid Receptors and Their Potential Applications,” Department of Chemistry, University of Sydney, Sydney, Australia, November 16, 2018.
- “Drug Discovery in Academia: Navigating the Path from the Bench to the Clinic,” panel discussant, Royal Australian Chemical Institute Bioactive Discovery and Development Group event, Sydney, Australia, November 15, 2018.
- “*In vivo* vs. *in vitro* Screening of Opioid Peptides: Novel Peptides that Don’t Follow the Rules,” Brain Institute, Florida Atlantic University, September 25, 2018.
- “Peptide Ligands for Kappa Opioid Receptors,” Bandung Institute of Technology, School of Pharmacy, Bandung, Indonesia, July 6, 2018
- “Novel Opioid Macrocyclic Peptides: Small Changes in Structure have Significant Impact on Their *in vivo* Activity,” Center for Substance Abuse Research, Temple University, August 23, 2016.
- “Novel Macrocyclic Tetrapeptides with Opioid Activity: Small Changes in Structure have Significant Impact on Their *in vivo* Activity,” UF Drug Discovery Symposium, University of Florida, April 29, 2016.
- “Novel Opioid Peptides: New Approaches for an Old Target,” Department of Medicinal Chemistry, Purdue University, May 5, 2014.
- “Novel Opioid Peptides: Potential for Drug Development,” Department of Medicinal Chemistry, University of Florida, April 22, 2014.
- “Novel Opioid Peptides: New Approaches for an Old Target,” the Fourth Annual Wanabe Symposium in Chemical Biotechnology, Department of Chemistry, Indiana University, October 12, 2013.
- “Peptidic Ligands for Kappa Opioid Receptors: Potential for Drug Development,” Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, February 5, 2013.
- “Peptidic Ligands for Kappa Opioid Receptors: Potential for Drug Development,” Center for Substance Abuse Research, Temple University, August 23, 2012.
- “Peptidic Ligands for Kappa Opioid Receptors: Potential for Drug Development,” 7th Leroy B. Townsend lecture, Department of Medicinal Chemistry, University of Michigan, May 17, 2012.
- “Peptidic Ligands for Kappa Opioid Receptors: Potential for Drug Development,” University of Colorado School of Medicine, Denver, April 13, 2011.
- “Peptide Kappa Opioid Receptor Ligands: Pharmacological Tools and Potential for Drug Development,” McLean Hospital, Boston, MA, April 5, 2010.

- “Peptide Kappa Opioid Receptor Ligands: Pharmacological Tools and Potential for Drug Development,” Department of Pharmaceutical and Biomedical Sciences, University of Georgia, February 22, 2010.
- “Peptide Opioid Receptor Ligands: Pharmacological Tools and Potential for Drug Development,” Department of Medicinal Chemistry, University of Minnesota, February 2, 2010.
- “Peptide Kappa Opioid Receptor Ligands: Pharmacological Tools and Potential for Drug Development,” Higuchi Bioscience Center Science Talks, University of Kansas, October 30, 2009.
- “Peptide Kappa Opioid Receptor Ligands: Pharmacological Tools and Potential for Drug Development,” Adolor Corporation, Exton, PA, September 1, 2009.
- “Peptide Opioid Receptor Ligands: Pharmacological Tools and Potential for Drug Development,” Center of Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, August 31, 2009.
- “Peptide Opioid Receptor Ligands: Pharmacological Tools and Potential for Pharmacological Development,” Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, August 4, 2009
- “Peptide Kappa Opioid Receptor Ligands: Pharmacological Tools and Potential for Pharmacological Development,” Laboratory of Biology of Addictive Diseases, Rockefeller University, New York, NY, April 7, 2009.
- “Development of Centrally Acting Opioid Peptide Analogs,” Abbott Laboratories, Abbott Park, IL, April 8, 2008.
- “Design and Pharmacological Activity of Peptidic Ligands for Kappa Opioid Receptors,” Creighton University School of Medicine, Department of Pharmacology, Omaha, NE, November 30, 2007.
- “Peptide Analogs as Tools to Study Receptors: a Tale of Two Labels, Three Receptors and Many More Questions,” Higuchi Bioscience Center Science Talks, University of Kansas, November 30, 2006.
- “Design, Synthesis and Evaluation of Peptidic Ligands for Kappa Opioid Receptors,” Department of medicinal Chemistry, School of Pharmacy, University of Mississippi, Oxford, MS, November 7, 2006.
- “Design, Synthesis and Evaluation of Peptidic Ligands for Kappa Opioid Receptors, Department of Pharmacology and Physiology, School of Veterinary Medicine, University of Georgia, Athens, GA, March 27, 2006.
- “The Design, Synthesis and Pharmacological Evaluation of Opioid Peptide Analogs as Tools to Study Opioid Receptors” Department of Chemistry, Hamline University, St. Paul, MN, June 6, 2005.
- “Novel Dynorphin A Analogs as Kappa Opioid Receptor Ligands,” Department of Pharmacology, Temple University, Philadelphia, PA, August 24, 2004.
- “A Tale of Two Labels: the Design and Synthesis of Dual Labeled Peptides as Pharmacological Tools,” Department of Physiology and Pharmacology, Oregon Health Sciences University, Portland, OR, April 7, 2004.

- “Design of Opioid Peptide Analogs to Study Opioid Receptors,” University of Michigan, September 6, 2002.
- “Design and Synthesis of Novel Labeled Opioid Peptide Derivatives for Opioid Receptors: a Tale of Two Labels,” University of Minnesota, Symposium in Honor of Philip S. Portoghese, August, 2001.
- “Design and Synthesis of Dynorphin A Analogues as Ligands for Kappa Opioid Receptors,” University of Kansas, Department of Medicinal Chemistry, College of Pharmacy, Lawrence, KS, September, 2000.
- “Design and Synthesis of Dynorphin A Analogues as Ligands for Kappa Opioid Receptors,” University of Iowa, Division of Medicinal and Natural Product Chemistry, College of Pharmacy, Iowa City, IA, September, 2000.
- “Design and Synthesis of Dynorphin A Analogues as Ligands for Kappa Opioid Receptors,” Interdepartmental Program in Medicinal Chemistry, University of Michigan, Ann Arbor, MI, September, 2000.
- “Design and Synthesis of Dynorphin A Analogues as Ligands for Kappa Opioid Receptors,” National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, June 1, 2000.
- “Design and Synthesis of Dynorphin A Analogues as Ligands for Kappa Opioid Receptors,” University of Connecticut, Department of Pharmaceutical Sciences, School of Pharmacy, October 25, 1999.
- “Design and Synthesis of Peptide-based Affinity Labels for Opioid Receptors,” Guilford Pharmaceuticals, Baltimore, MD, December 8, 1998.
- “Design and Synthesis of Peptide-based Affinity Labels for Opioid Receptors,” North Carolina State University, Chemistry Department, Raleigh, NC, October 13, 1998.
- “Design and Synthesis of Peptide-based Affinity Labels for Opioid Receptors,” Research Triangle Institute, Research Triangle Park, NC, October 12, 1998.
- “Design and Synthesis of Peptide-based Affinity Labels for Opioid Receptors,” University of Maryland, Department of Microbiology and Immunology, Baltimore, MD, April 8, 1998.
- “Design and Synthesis of Peptide-based Affinity Labels for Opioid Receptors,” University of Kansas, Department of Medicinal Chemistry, College of Pharmacy, Lawrence, KS, January 15, 1998.
- “Design and Synthesis of Opioid Peptide Analogues,” National Institute of Dental Research, Bethesda, MD, May 1, 1997.
- “Peptide-Based Affinity Labels for Opioid Receptors,” University of Minnesota, Department of Medicinal Chemistry, College of Pharmacy, Minneapolis, MN, January 14, 1997.
- “Design and Synthesis of Biologically Active Peptides and Peptidomimetics,” University of Maryland, Institute of Human Virology, Baltimore, MD, September 16, 1996.
- “Synthesis of Opioid Peptide Derivatives as Potential Affinity Labels for Opioid Receptors,” Wayne State University, School of Pharmacy, Detroit, MI, April 18, 1996.

V. GRANTS AND CONTRACTS

Present Support:

Source: Department of Defense W81XWH2210268
Title: Targeting CIP2A as Potential Treatments for Ovarian Cancer
Principal Investigator: Jane V. Aldrich (7.5% effort)
Amount requested: \$381,250 total costs (\$250,000 total direct costs)
Period requested: May 1, 2022-April 30, 2024

Source: NINDS/NIDA 1UG3 NS132600-01
Title: Cyclic Peptides to Treat Cocaine Disorder
Principal Investigators: Jane V. Aldrich (30% effort), Jay McLaughlin (20% effort), Jean Bidlack (University of Rochester, 20% effort)
Amount: \$945,941 total costs (\$686,775 direct costs)
Period: May 15, 2023 – April 30, 2024 (UG3)

Source: Parkinson's Foundation
Title Exploration of compounds that target alpha-synuclein phosphorylation
Principle Investigator: Jane Aldrich (5% effort)
Co-investigator: Paramita Chakrabarty (5% effort)
Amount: \$150,000 total costs (\$135,000 direct costs)
Period: July 1, 2023 – June 30, 2024

Past support:

Source: University of Florida Research Opportunity Fund
Title: Exploration of the SIM2 Class as Potential Novel Peptide Anticancer Therapeutics
Principle Investigator: Jane V. Aldrich (7.5% effort); Daiqing Liao (5% effort), co-principle investigator
Amount: \$85,000 direct costs
Period: July 15, 2020 – December 31, 2022

Source: University of Florida PROSPER award
Title: Assessing Allosteric Mechanisms of Opioid Signaling
Principle Investigators: Jane V. Aldrich, Jay P. McLaughlin, and Siobhan Malany (5% effort each)
Amount: \$36,000 direct costs
Period: March 1, 2020 – December 30, 2021

Source: Department of Defense, PC130736
Title: A Novel Strategy for Prostate Cancer Therapy Targeting the c-Myc Oncoprotein
Principal Investigator: Jane V. Aldrich (10% effort)
Amount: \$502,460 total costs, \$334,973 total direct costs
Period: August 18, 2014 – May 15, 2015 and June 28, 2018 – December 17, 2021

Source: National Institute on Drug Abuse, R01 DA023924-08
Title: Peptidic Kappa Opioid Receptor Ligands as Potential Treatments for Drug Addiction

Principal Investigator: Jane V. Aldrich (12% effort)
Co-investigators: Jay P. McLaughlin (17.5% effort), Guenther Hochhaus (4% effort), and
Thomas F. Murray (10% effort, Creighton University)
Amount: \$3,275,558 total costs \$2,315,342 total direct costs)
Period: June 15, 2014 – March 31, 2021 (no cost extension)

Source: Department of Defense, PR141230
Title: Novel Peptide Antagonists as Treatments for Substance Abuse
Principal Investigator: Jane V. Aldrich (15% effort)
Co-investigator: Guenther Hochhaus (5% effort)
Amount: \$1,075,142 total costs (\$716,761 total direct costs)
Period: September 1, 2015 – August 31, 2020 (no cost extension)

Source: National Institute on Drug Abuse
Title: Peptidic Ligands for κ Opioid Receptors, R01 DA18832-10
Principal Investigator: Jane V. Aldrich (5.7% effort)
Co-Investigators: Jay P. McLaughlin (5% effort) and Thomas F. Murray (Creighton University, 5% effort)
Amount: \$1,501,986 total costs (\$1,188,946 total direct costs)
Period: March 1, 2012 – February 28, 2018 (no cost extension)

Source: National Institute on Drug Abuse, R01 DA032928-03
Title: Development of Novel Opioid Peptides for Cocaine Abuse
Principal Investigator: Jane V. Aldrich (11.25% effort)
Co-Investigators: Susan L. Lunte (6.25% effort), Thomas F. Murray (Creighton University, 5% effort), Jay P. McLaughlin (Torrey Pines Institute for Molecular Studies, 20% effort), Mary Jeanne Kreek (Rockefeller University, 5% effort)
Amount: \$2,052,902 total costs (\$1,748,917 total direct costs)
Period: March 1, 2012 - February 28, 2016 (no cost extension)

Source: University of Kansas J. R. & Inez Jay Fund
Title: Novel Compounds with Anticancer Activity
Principal Investigator: Jane V. Aldrich
Co-investigator: Benyi Li (University of Kansas Medical Center)
Amount: \$30,000
Period: July 1, 2013 – June 30, 2014, extended to February 28, 2015

Source: National Institute of Neurological Disorders and Stroke, R01 NS04929-08
Title: Analytical Methods for Investigating Peptide Transport
Principal Investigator: Susan M. Lunte
Role on project: Co-investigator (5% effort)
Amount: \$1,250,000 total direct costs
Period: July 1, 2008 – June 30, 2013 (extended to June 30, 2014)

Source: National Institute on Drug Abuse, R01 DA023924-(01-05)
Title: Peptidic Kappa Opioid Receptor Ligands as Potential Treatments for Drug Addiction
Principal Investigator: Jane V. Aldrich (12% effort)

Co-investigators: Susan M. Lunte (5% effort), Thomas F. Murray (10% effort, Creighton University) and Jay P. McLaughlin (10%, Torrey Pines Institute for Molecular Studies)
Amount: \$2,158,278 total costs (\$1,758,783 total direct costs)
Period: September 15, 2007 – August 31, 2012 (extended to August 31, 2013)

Source: National Institute on Drug Abuse, R01 DA010035-(10-11)
Title: Affinity Labels for Opioid Receptors
Principal Investigator: Jane V. Aldrich (8.3% effort)
Co-investigator: Thomas F. Murray (Creighton University, 8.3% effort)
Amount: \$622,810 total costs (\$486,834 total direct costs)
Period: August 1, 2009 – July 31, 2011 (extended to July 31, 2012)

Source: University of Kansas Cancer Center
Title: A Novel Strategy for Delivery of Anticancer Agents to the Brain
Principal Investigator: Jane V. Aldrich (10% effort)
Co-investigators: Susan M. Lunte (5% effort), and Kenneth Audus (2% effort)
Amount: \$35,000
Period: January 1 – December 31, 2009 (extended to June 30, 2011)

Source: University of Kansas Institute for Advancing Medical Innovation
Title: A Novel Strategy for Brain Drug Delivery
Principal Investigator: Jane V. Aldrich (8.3% effort)
Co-investigators: Susan M. Lunte (4% effort), Mary Lou Michaelis (4% effort), and Kenneth Audus (2% effort)
Amount: \$77,005
Period: September 15, 2009 – March 31, 2011

Source: National Institute on Drug Abuse, R01 DA18832-05
Title: Peptidic Ligands for κ Opioid Receptors
Principal Investigator: Jane V. Aldrich (16.7% effort)

Co-Investigators: Gerald Lushington (3% effort)
Thomas F. Murray (Creighton University, 10% effort)
Amount: \$1,387,205 total costs (\$1,055,295 total direct costs)
Period: February 15, 2005 - February 14, 2010 (extended to February 14, 2011)

Source: National Institute on Drug Abuse, R01 DA18832-03S1
Title: Minority Supplement: Peptidic Ligands for κ Opioid Receptors
Principal Investigator: Jane V. Aldrich
Amount: \$170,020 total costs (\$118,070 total direct costs)
Period: August 15, 2007 - February 14, 2010 (extended to February 14, 2011)

Source: National Institute on Drug Abuse, K02 DA00393-(06-11) (Independent Scientist Award)
Title: Opioid Peptide Analogs as Probes of Opioid Receptors

Principal Investigator: Jane V. Aldrich [†]

Amount: \$650,919 total costs (\$602,704 total direct costs)

Period: September 1, 2004 - August 31, 2009 (extended to August 31, 2010)

Source: National Institute on Drug Abuse, R01 DA023924-02S1

Title: Supplement to Peptidic Kappa Opioid Receptor Ligands as Potential Treatments for Drug Addiction

Principal Investigator: Jane V. Aldrich (12% effort)

Amount: \$36,500 total costs (\$25,000 direct costs)

Period: September 1, 2008 – August 31, 2009 (extended to August 31, 2010)

Source: National Institute on Drug Abuse, R01 DA10035-(05-09)

Title: Affinity Labels for Opioid Receptors

Principal Investigator: Jane V. Aldrich (25% effort)

Co-Investigator: Thomas F. Murray (Creighton University, 10% effort)

Amount: \$1,155,989 total costs (\$875,000 total direct costs)

Period: April 1, 2003 – March 31, 2008 (extended to March 31, 2009)

Source: National Institute on Drug Abuse, R01 DA10035-07S1

Title: Minority Supplement: Affinity Labels for Opioid Receptors

Principal Investigator: Jane V. Aldrich

Amount: \$185,623 total costs (\$129,905 total direct costs)

Period: August 1, 2005 – March 31, 2008 (extended to March 31, 2009)

Source: National Institute of Neurological Disorders and Stroke, R56 NS042929-06

Title: Analytical Methods for Investigating Peptide Transport

Principal Investigator: Susan M. Lunte

Role: Co-Investigator

Amount: \$250,000 direct costs

Period: July 1, 2007 – June 30, 2008

Source: University of Kansas General Research Fund

Title: Blood-Brain Barrier Transport of Basic Opioid Peptides

Principal Investigator: Jane V. Aldrich

Co-Investigators: Kenneth Audus, Susan M. Lunte

Amount: \$7,000 total/direct costs

Period: July 1, 2004 – June 30, 2005

Source: National Institute on Drug Abuse, R01 DA05195-(08-11)

Title: Dynorphin Analogues as κ Opioid Receptor Antagonists

Principal Investigator: Jane V. Aldrich (33% effort)

Co-Investigators: Ronald Guiles (5% effort), Alexander McKerell (5%), Jia Bei Wang (5%)

University of Georgia: Thomas F. Murray (10% effort)

Amount: \$806,725 total costs (\$606,062 total direct costs)

Period: August 20, 1997 - June 30, 2001 (extended to July 31, 2002)

[†] This career development award covered 75% of the awardee's salary so that the awardee could devote at least 75% of her time to research.

Source: National Institute on Drug Abuse, R01 DA10035-(01-04)
Title: Affinity Labels for Opioid Receptors
Principal Investigator: Jane V. Aldrich (25% effort)
Co-Investigators: Thomas F. Murray (10% effort), Jai Bei Wang (5% effort)
Amount: \$696,245 total costs (\$405,314 total direct costs)
Period: September 1, 1996 - July 31, 2000 (extended to July 31, 2001)

Source: University of Maryland School of Pharmacy Designated Research Initiative Funds
Title: Design, Synthesis and Pharmacological Evaluation of Orphanin FQ Analogues as
Ligands for the ORL1 Receptor
Principal Investigator: Jane V. Aldrich (10% effort)
Co-Investigator: Jia Bei Wang (5%)
Amount: \$25,250
Period: July 1, 1998 - January 31, 2000

Source: National Institute on Drug Abuse
Title: Supplement to Dynorphin Analogues as κ Opioid Receptor Antagonists (R01 DA05195)
Principal Investigator: Jane V. Aldrich
Amount requested: \$37,920 total costs (\$33,500 total direct costs)
Period: April 15, 1999 - June 30, 1999

Source: U. S. Army Medical Research and Material Command, Breast Cancer Research
Program
Title: Novel Irreversible Inhibitors of Cathepsin D
Principal Investigator: Jane V. Aldrich (10% effort)
Amount: \$149,916 total costs (\$107,425 total direct costs)
Period: July 1, 1996 - June 30, 1998 (extended to June 30, 1999)

Source: UMAB School of Pharmacy DRIF
Title: Novel Dynorphin Analogues as Kappa Opioid Receptor Ligands
Principal Investigator: Jane V. Aldrich (10% effort)
Co-Investigator: Jia Bei Wang (5%)
Amount: \$10,000
Period: July 1, 1996 - June 30, 1997

Source: National Institute on Drug Abuse, R01 DA05195-(04-07)
Title: Dynorphin Analogues as κ Opioid Receptor Antagonists
Principal Investigator: Jane V. Aldrich (40% effort)
Co-Investigators: Gary E. DeLander (10% effort), Thomas F. Murray (10% effort)
Amount: \$570,099 total costs (\$409,363 total direct costs)
Period: August 1, 1993 - June 30, 1996 (extended to June 30, 1997)

Source: National Science Foundation, Neuroscience Program, IBN-9023149
Title: Affinity Labels for Kappa Opioid Receptors
Principal Investigator: Jane V. Aldrich (25% effort)
Co-Investigators: Thomas F. Murray (10% effort), Gary E. DeLander (5% effort)
Amount: \$190,018 total costs (\$138,529 total direct costs)

Period: March 15, 1991 - August 31, 1995

Source: National Institute on Drug Abuse, R01 DA05195 (-01 to -03)

Title: Dynorphin Analogs as κ Opioid Receptor Antagonists

Principal Investigator: Jane V. Aldrich (50% effort)

Co-Investigators: Gary E. DeLander (10% effort), Thomas F. Murray (10% effort)

Amount: \$460,398 total costs (\$343,530 total direct costs)

Period: September 30, 1989 - August 31, 1993

Source: Alcohol, Drug Abuse, and Mental Health Administration, Small Instrumentation Program

Title: ASIP - Oregon State University

Principal investigator: Thomas F. Murray

Co- Investigator: Jane V. Aldrich

Amount: \$26,618

Period: September 1, 1992 - August 31, 1993

Equipment grant

Source: Oregon State University Research Office

Title: Release Time for Proposal Development

Recipient: Jane V. Aldrich

Amount: \$5,500

Period: Winter quarter, 1993

Source: Oregon State University Research Council

Title: Synthesis and Evaluation of Constrained Dynorphin A Analogues

Principal Investigator: Jane V. Aldrich (10% effort)

Co-Investigators: Gary E. DeLander (5% effort), Thomas F. Murray (5% effort)

Amount: \$8,000

Period: November 18, 1992 - June 30, 1993

Source: National Science Foundation, Research Experience for Undergraduates Supplement

Title: Affinity Labels for Kappa Opioid Receptors

Principal Investigator: Jane V. Aldrich

Amount: \$3,660

Period: January 1, 1992 - August 31, 1992

Source: American Association of Colleges of Pharmacy Grant Program for Young Investigators

Title: Irreversible Antagonists of the Delta Opioid Receptor

Principal Investigator: Jane V. Aldrich (10% effort)

Amount: \$5,000

Period: November 3, 1987 - October 31, 1991

Source: Pharmaceutical Manufacturers Association Foundation Research Starter Grants

Title: Pharmacological Probes of Kappa Opioid Receptor Subtype Function

Principal Investigator: Jane V. Aldrich (15% effort)

Co-Investigators: Gary E. DeLander (5% effort), Thomas F. Murray (5% effort)

Amount: \$20,000

Period: January 1, 1988 - December 30, 1990

Source: Medical Research Foundation of Oregon

Title: N-Alkylated Dynorphin Analogs as Kappa Opioid Receptor Antagonists

Principal Investigator: Jane Aldrich Lovett[‡] (15% effort)

Amount: \$11,830

Period: December 1, 1987 - November 30, 1989

Source: Oregon State University Research Council

Title: Dynorphin Analogs as Kappa Opioid Receptor Ligands

Principal Investigator: Jane Aldrich Lovett (10% effort)

Co-Investigator: Gary E. DeLander (5% effort)

Amount: \$8,000

Period: September 28, 1987 - September 28, 1988

Source: National Institutes of Health Individual Research Service Award

Title: Opioid Peptide Analogs as K Opiate Receptor Antagonists

Awardee: Jane Aldrich Lovett (100% effort)

Amount: \$37,233

Period: April 1984 - January 1986

Postdoctoral Fellowship

Selected recent grants submitted but not funded:

Source: National Institutes of Neurological Disorders and Stroke (UG3/UH3)

Title: Cyclic Peptides to Restrict Pain Chronification

Principal Investigators: Jane V. Aldrich (30% effort) and Jay McLaughlin (20% effort)

Co-investigators: Guenther Hochhaus (15% effort), Siobhan Malany (10% effort) and Prentice Boone (5% effort)

Amount requested: \$5,047,427 total costs, \$3,327,459 direct costs

Period: November 1, 2022 – October 31, 2027

RESEARCH PERSONNEL

A. Master and Doctoral Students Supervised

1. Degrees Completed

University of Florida

Jeremy Coleman, “Design and Synthesis of Didehydro-cortistatin A Analogs as Novel TAT inhibitors for the Potential Treatment of HIV, Ph.D., May 27, 2021.

Current position: Postdoctoral associate, Vanderbilt University

Robyn Pescatore, “Macrocyclic Tetrapeptides as Potential Prostate Cancer Therapeutics,” Ph.D., June 29, 2020.

Current position: Scientist 1, BioAgilytix

[‡] Former name

Jan-Louis Cosme, non-thesis masters, May, 2020.

Current position: Forensic chemist, Florida Department of Law Enforcement

University of Kansas

Solomon A. Gisemba, "Design and Synthesis of Cyclic Analogs of the Kappa Opioid Receptor Antagonist Aroclon," Ph.D., April 18, 2018.

Current position: Design Transfer – Medical Devices, Accelerate

Benjamin Mann (co-advisor with Susan Lunte), "Determination of Pharmacokinetic Parameters of Subcutaneous Zyklophol by Quantitative Determination of Zyklophol in Mouse Plasma by LCMS/MS Analysis for Assessment As A Potential Therapeutic Agent In The Treatment of Cocaine Addiction," M.S., Pharmaceutical Chemistry, December 13, 2016.

Christianna Reedy, "Assessing ADME Properties of CJ-15,208: Synthesis of New Analogs and Examination of P-glycoprotein Interactions" M.S., August 28, 2015.

Anand Joshi, "Synthesis and Biological Evaluation of Dynorphin Analogs, and Caco-2 Permeability of Opioid Macrocyclic Tetrapeptides," Ph.D., May 17, 2013

Current position: Senior Scientist II, Abbvie

Wendy J. Hartsock, "The Design, Synthesis and Evaluation of Peptide Ligands to Study Opioid Receptors," Ph.D., July 22, 2010

Current position: Director of Scientific Acceleration, CEM Corporation

Bhaswati Sinha, "Design, Synthesis and Evaluation of Peptide-Based Affinity Labels for Mu Opioid Receptors," Ph.D., July 9, 2009

Current position: Lead, Technical Writing Team, Thermo Fisher

Kendra Dresner, "Design, Synthesis and Metabolism of Aroclon Analogs," M.S., January 20, 2009.

Weijie Fang, "Design and Synthesis of Novel Linear and Cyclic Peptide Ligands for Kappa Opioid Receptors," Ph.D., August 28, 2008

Current position: Associate Professor, Zhejiang University, Hangzhou, Zhejiang, China

Angela Peck, "Dual Labeled TIPP (Tyr-Tic-Phe-Phe, Tic = 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) Peptides as Pharmacological Tools to Study Delta Opioid Receptors," M.S. June 7, 2007.

Xin Wang, "Progress Towards Affinity Labeling of δ Opioid Receptors," Ph.D., September 21, 2007.

University of Maryland Baltimore

Marco Bennett, "Synthesis and Evaluation of Opioid Activity of Novel Dynorphin A-(1-11) Analogues using Classic and Combinatorial Library Approaches," Ph.D., June 2003

Current position: Regulatory Review Officer, Food and Drug Administration

Chris Sasiela, Ph.D., April, 2002.

Current position: Innovator Support Team Lead, Senior Regulatory Specialist, Office of Extramural Research, National Institutes of Health

Kshitij Patkar, "Design and Synthesis of [N^{α} -BenzylTyr¹]Dynorphin A-(1-11) Analogs with C-terminal Modifications, Evaluation of Their Opioid Activity and Blood-Brain Barrier Transport Ph.D. November, 2002.

Current position: Regulatory Review Officer, Food and Drug Administration

Balvinder Vig, "Synthesis and Pharmacological Evaluation of Dynorphin A Analogs Constrained in the "Message" Sequence," Ph.D, September 2001.

Current position: Senior Director, Global Quality Analytical Science and Technology,
Bristol Myers Squibb
Laksana Charoenchai, "Design, Synthesis and Evaluation of Orphanin FQ-(1-13)NH₂ Analogs,"
Ph.D., July 2001.
Current position: Rangsit University, Thailand
Tianxin Wang, "Synthesis and Biological Evaluation of Novel Ligands for Opioid Receptors,"
M.S., May 2001.
Current position: Quest Medicine, Inc.

Oregon State University

Dean Maeda, "Synthesis and Evaluation of Affinity Labels Based on Peptide Antagonists for
Delta Opioid Receptors," Ph.D., November 1997.
Current position: Director of Chemistry, Syntrix Biochip
Leena (Leelasvatanakij) Suntornsuk, "Synthetic Strategies for the Preparation of Affinity Label
Dynorphin A(1-11)NH₂ Analogues," Ph.D., April 1996.
Current position: Professor, Pharmaceutical Chemistry Department, Pharmacy Faculty,
Mahidol University, Bangkok, Thailand
Sandhya Kulkarni, "Synthesis and Opioid Activity of Dynorphin Analogues with the
Modifications in the Message Sequence," M.S., June, 1995.
Seksiri Arttamangkul, "Synthesis and Evaluation of Conformationally Constrained Analogues of
Dynorphin A," Ph.D., January 1995.
Current position: Research Assistant Professor, Department of Physiology and
Pharmacology, School of Medicine, Vollum Institute, Oregon Health Sciences
University
Heekyung Choi, "Synthesis and Biological Evaluation of Dynorphin Analogues as
Pharmacological Probes of Opioid Receptors," Ph.D., January 1995.
Leena (Leelasvatanakij) Suntornsuk, "Comparison and Optimization of Chromatographic
Conditions for the Separation of Cyclic Dynorphin A Analogues from Linear
Byproducts," M.S., August 1993.
Kristin Snyder, "Synthesis of Dynorphin A Analogues with Modifications in the "Message" and
"Address" Sequences," M.S. (Biochemistry and Biophysics, Oregon State University),
May 1993.
Sandra Vigil-Cruz Bartlett (Sandra Story[§]), "Solid Phase Synthesis of Dynorphin Analogues as
Probes of Kappa Opioid Receptors," Ph.D., May 1990.
Current position: Clinical Pharmacy Coordinator, Holyoke Medical Center

Awards received by students:

Christianna Reedy, NIGMS Biotechnology Training Grant trainee, 2013 – 2014.
Wendy Hartsock, American Foundation for Pharmaceutical Education Fellowship, 2007 – 2009.
Bhaswati DattaChowdhury, finalist in poster competition, 20th American Peptide Symposium,
Montreal, Canada, June 26-30, 2007.
Christy Sasiela:
National Institute on Drug Abuse, Individual National Research Service Award
(predoctoral fellowship), "Antiproliferative Activity of Opioid Analogues," June
1, 2000 - May 30, 2002.
American Foundation for Pharmaceutical Education Fellowship, 1999 - 2000.

[§] Former name

Marco Bennett:

National Institute on Drug Abuse, Individual National Research Service Award (minority predoctoral fellowship), "Synthesis and Activity of Novel Kappa Opioid Peptides," October 1, 2001 – September 30, 2003

Graduate Program Enrichment Fellowship, University of Maryland Baltimore, 2000 - 2001.

Travel grant awards received by the following students:

Robyn Pescatore to present her research at the 26th American Peptide Symposium, Monterey, CA, June, 2019.

Anand Joshi to present his research at the 22nd American Peptide Symposium, San Diego, CA, June, 2011.

Wendy Hartsock to present her research at the 2nd International Modern Solid Phase Peptide Synthesis and Its Applications Symposium, Gold Coast, Queensland, Australia, October 8-11, 2009.

Wendy Hartsock to present her research at the 21st American Peptide Symposium, Bloomington, IN, June, 2009.

Bhaswhati DattaChowdhury to present her research at the International Narcotic Research Conference, Charleston, S.C., July 13-18, 2008.

Bhaswhati DattaChowdhury, Weijie Fang, and Nicolette Ross to present their research at the 20th American Peptide Symposium, Montreal, Quebec, Canada, June 26-30, 2007

Weijie Fang to present his research at the Chemistry and Biology Gordon Research Conference, February 2006.

Xin Wang, Weijie Fang and Angela Peck to present their research at the 19th American Peptide Symposium/ 2nd International Peptide Symposium, San Diego, June 2005.

Matthew Leighty to present his research at the 18th American Peptide Symposium/ 2nd International Peptide Symposium, Boston, June 2003.

Marco Bennett, Kshitij Patkar, Christy Sasiela, and Balvinder Vig to present their research at the 17th American Peptide Symposium/ 2nd International Peptide Symposium, San Diego, June 2001.

Laksana Charoenchai and Balvinder Vig to present their research at the 16th American Peptide Symposium, Minneapolis, MN, June 26-July 1, 1999.

Balvinder Vig to present his research at the International Narcotic Research Conference, Sarasota Springs, N.Y., July 10-15, 1999.

Balvinder Vig (first place) and Laksana Charoenchai (second place), Chemistry II section, poster competition at the 21st Annual Graduate Student Research Day, University of Maryland, Baltimore, April 21, 1999.

Kshitij Patkar (first place) and Laksana Charoenchai (second place), chemistry poster session, 22nd Annual Graduate Student Research Conference (GRC), University of Maryland, Baltimore County, April 19, 2000.

Other students supervised (2001 – present):

University of Kansas:

Katherine Prevatt, 2007 – 2009

Yuping Yu, 2006 – 2007

Matthew Leighty, 2001 – 2005

Priyanka Chaudry, Fall 2003

Rotation students:

Fall, 2004 – Gagandeep Somal, Haleib Woldeab, and Bhaswati DattaChowdhury
Fall, 2005 – Karen Beckman, Chad Schroeder, and Yuping Yu
Fall, 2006 – Gary Brandt, Syed Wasimul Haque, Karrie Prevatt, and Angelica Meyer
Fall, 2007 – Chris Kimmel, Anand Joshi, Kyle Bailey, Linda Blake
Fall, 2010 – Euna Yoo
Fall, 2011 – Solomon Gisemba, Kayann Tabanor (Chemistry student)
Summer, 2012 – Vince Crowley, Christianna Reedy
Fall, 2013 – Doug Orsi

2. Service on Thesis and Examining Committees (2001 – present)

National/International

Soohyun Kwon, Ph.D., University of Queensland (Australia), external thesis examiner, 2016;
Mengie Liu, M.S., Monash University (Australia), external thesis examiner, 2012;
Cecil Cros, Ph.D., University of Queensland (Australia), external thesis examiner, 2009.

University of Florida:

Swapnil Joshi, Chemistry, Ph.D., oral candidacy exam, November 1, 2023;
Mallory Burns, Medicinal Chemistry, Ph.D., oral candidacy exam, December 15, 2020; thesis defense July 6, 2023;
Alexis Smith, Medicinal Chemistry, oral candidacy exam, December 15, 2022;
Breanne Freeman, Medicinal Chemistry, oral candidacy exam, November 17, 2022;
Morgan Crowley, Medicinal Chemistry, Ph.D., oral candidacy exam, January 15, 2021; thesis defense July 5, 2022;
Dake Liu, Medicinal Chemistry, Ph.D., oral candidacy exam, June 3, 2020; thesis defense June 30, 2022;
Dillon Rickerson, Chemistry, Ph.D., oral candidacy exam, April 18, 2022;
Lijun Lang, Chemistry, Ph.D., oral candidacy exam, November 18, 2021;
Ariana Brice-Tutt, Ph.D, Pharmacodynamics, oral candidacy exam, October 8, 2019; thesis defense March 10, 2021;
Qiang Li, Chemistry, Ph.D., oral candidacy exam, November 2, 2017; thesis defense March 23, 2021;
Kareem Galal, Medicinal Chemistry, Ph.D., oral candidacy exam, May 8, 2018; thesis defense March 19, 2020;
Peilan Zhang, Medicinal Chemistry, Medicinal Chemistry, Ph.D., oral candidacy exam, February 19, 2018; thesis defense March 6, 2020;
Sarah Scott, Chemistry, Ph.D., oral candidacy exam, November 1, 2017; thesis defense March 12, 2020;
Miles Rubinski, Chemistry, Ph.D., oral candidacy exam, February 25, 2016.

University of Kansas (2001 – 2015):

Alex Salyer, Medicinal Chemistry, Ph.D. oral candidacy exam, November 5, 2014
David Hymel, Medicinal Chemistry, PhD., thesis defense, July 11, 2014
Sara (Logan) Thomas, Chemistry, Ph.D. candidate, oral candidacy exam May 6, 2008; thesis defense January 23, 2014

Cameron Ng, Medicinal Chemistry, Ph.D. oral candidacy exam, November 21, 2013
 Kayan Tabanor, Chemistry, Ph.D. oral candidacy exam, June 3 and October 31, 2013
 Molly Lee, Medicinal Chemistry, Ph.D. oral candidacy exam, June 19, 2013
 Derek White, Pharmaceutical Chemistry, Ph.D. oral candidacy exam, May 23, 2013
 Abdullah Al-Hossaini, Pharmaceutical Chemistry, Ph.D. oral candidacy exam, May 20, 2103
 Yunan Wang, Chemistry, Ph.D. oral candidacy exam, February 14, 2013, oral research proposal
 November 12, 2012
 Sean Willis, Chemistry, M.S. thesis defense, December 13, 2012
 Elyse Petrunak, Medicinal Chemistry, Ph.D. oral candidacy exam, June 29, 2012
 Linda Blake, Ph.D., oral candidacy exam March 10, 2010; thesis defense, April 3, 2012
 Courtney Kuhnline Sloan, Ph.D., Pharmaceutical Chemistry, thesis defense February 11, 2011
 Erin Hirt, Medicinal Chemistry, PhD., oral candidacy exam June 16, 2006; thesis defense August
 28, 2009
 Michael Szostack, Medicinal Chemistry, Ph.D. candidate, oral candidacy exam May 30, 2007
 Arvind Chappa, Pharmaceutical Chemistry, Ph.D., oral candidacy exam; thesis defense March 8,
 2007
 Huijong Han, Medicinal Chemistry, PhD. candidate, oral candidacy exam August 23, 2006
 Jin Liu, Medicinal Chemistry, Ph.D., thesis defense 2005
 Anthony Romero, Medicinal Chemistry, Ph.D., thesis defense August 11, 2004
 Kevin Poon, Chemistry, Ph.D., oral candidacy exam July 17, 2002; thesis defense July 28, 2004

D. Postdoctoral Associates, Research Associates, Research Assistants Supervised

Current:

Dr. Laura Hanold	August, 2016 – present
Postdoctoral Associate	August, 2016 – August, 2021
Research Associate	August, 2021 – present
Dr. Moustafa Hamaad	February, 2024 - present

Previous

Dr. Dmitry Yakolev	April, 2010 – December, 2021
Research Associate	
Dr. Tatyana Yakovleva	April, 2009 – May, 2021
Research Associate	2004 – February 2007 (supervised jointly by Dr. Sandra Vigil Cruz Bartlett and myself)
Research Associate	February, 2007 – May, 2021
Dr. Tanvir Khaliq	December, 2010 – May, 2021
Postdoctoral Associate	December, 2010 – October, 2013
Research Associate	November, 2013 – May, 2021
Dr. Solomon Gisemba	June, 2018 – October, 2020
Postdoctoral Associate	
Grant Simpson	August 2016 – September 2017
Research Assistant	
Dr. Michael Ferracane	October, 2014 – June, 2016
Postdoctoral Associate	
Dr. Archana Mukhopadhyay	October, 2010 – June, 2016
Postdoctoral Associate	January, 2010 – October, 2011

Research Associate, November, 2011 – June, 2016
Dr. Sanjeewa Senadheera January, 2010 – March, 2015
Postdoctoral Associate, January, 2010 – December, 2013
Research Associate, December, 2013 – March, 2015
Dr. Kshitij Patkar February, 2006 – July, 2010
Dr. Sandra Vigil-Cruz Bartlett September 1990 - September 1992, June 1995 – August 1997
Research Asst. Prof./ Senior Research Associate, July, 2001 – June, 2010
Dr. Nicolette Ross January, 2007 – August, 2009
Dr. Mark Del Borgo March, 2007 – July, 2008
Dr. Santosh Kulkarni December, 2005 – October, 2007
Research Associate
Dr. Heekyung Choi April 1997 – January 2003
Dr. Vivek Kumar September 1997 – May 2001
Dr. Praveen Marapaka March 1999 - July, 2000
Dr. Dean Maeda January 1998 - July 1999
Dr. Qi Zheng December 1993 - January 1997
Dr. Nishith Chatervedi October 1990 - September, 1991

Awards received:

Laura Hanold, Poster award, University of Florida Health Cancer Center Virtual Symposium, December, 2020.
Travel award to postdoctoral associate Solomon Gisemba to present his research at the 26th American Peptide Symposium, Monterey, CA, June, 2019.
Travel award to postdoctoral associate Laura Hanold to present her research at the 26th American Peptide Symposium, Monterey, CA, June, 2019.
Michael Ferracane, Bert Schram Young Investigator Award, American Peptide Symposium, Orlando, FL, June 20-25, 2015.
Travel award to postdoctoral associate Michael Ferracane to present his research at the 24th American Peptide Symposium, Orlando, FL, June 20-25, 2015.
Travel award to research associate Tanvir Khaliq to present his research at the 248th American Chemical Society National Meeting, San Francisco, CA, August 10-13, 2014.
Sanjeewa Senadheera, *ACS Medicinal Chemistry Letters* poster award, 246th American Chemical Society National Meeting, Indianapolis, IN, September 8-12, 2013.
Travel award to postdoctoral associate Sanjeewa Senadheera to present his research at the 246th American Chemical Society National Meeting, Indianapolis, IN, September 8-12, 2013.
Travel award to postdoctoral associate Sanjeewa Senadheera to present his research at the 22nd American Peptide Symposium, San Diego, CA, June 25-30, 2011.
Travel award to postdoctoral associate Nicolette Ross to present her research at the International Narcotic Research Conference, Charleston, SC, July 13-18, 2008.
Awards received by postdoctoral associate Heekyung Choi:
Selected as one of twelve presenters (from 50+ applicants) in the Young Investigator Symposium at the 16th American Peptide Symposium, Minneapolis, MN, June 26, 1999.
Received a travel grant to present her research at the 16th American Peptide Symposium, Minneapolis, MN, June 26-July 1, 1999

E. Undergraduate Students, etc. Supervised (2015 - present):

University of Florida:

Julia Hetzel, PharmD student, May, 2022 – present;

Kelly Feifel, February, 2023 – present;

Katherine Figueroa, September 2023 – present;

Ryan Self, January – October, 2023;

Asiah Cheek, Edward Waters College, Research Training Opportunities for Outstanding Leaders (ReTOOL) Program, May – July, 2019;

Lara Wolff, University of South Florida, Summer Undergraduate Research at Florida (SURF), May – August, 2019;

Iyosayi Urhoghide, Florida A&M University, Research Training Opportunities for Outstanding Leaders (ReTOOL) Program, May – July, 2018;

Michelle Adkins, PharmD student, January – May, 2018;

Sophia Mourad, September, 2017 – May, 2018 and August, 2018 – May, 2019;

Stefan Cevallos, July, 2017 – May, 2018;

Hans Tchienga, University of Toledo, Summer Undergraduate Research at Florida (SURF), May – August, 2017;

Cassandra Walker, Florida A&M University, Research Training Opportunities for Outstanding Leaders (ReTOOL) Program, May – July, 2016;

Ted Lee, PharmD student, October-December, 2015.

VI. TEACHING**Courses Taught 2001 - present*****University of Florida (2015 – present)**

<u>Course Number</u>	<u>Course Name (no. of credits)</u>	<u>Semester</u>	<u>Course-coordinator?</u>	<u>No. contact hrs.</u>
<u>Graduate courses:</u>				
PHA 6447	Drug Design (3)	Fall, 2023		14 lectures/exams
		Fall, 2022		11 lectures/exams
		Fall, 2021		11 lectures/exams
		Fall, 2020		11 lectures/exams
		Fall, 2019		11 lectures/exams
		Fall, 2018		11 lectures/exams
		Fall, 2017		11 lectures/exams
		Fall, 2015		7 lectures/exams
PHA 6935	Drug Design II (3)	Spring, 2023		5 lectures/exams
		Spring, 2022		4 lectures/exams
		Spring, 2021		4 lectures/exams
		Spring, 2020		4 lectures/exams
		Spring, 2019		4 lectures/exams
		Spring, 2018		4 lectures/exams
PHA 6934	Seminar	2023-2024		Course coordinator
		2022-2023		Course coordinator
		Spring, 2022		1 lecture
PHA 6936	Grant Writing	Summer, 2023		4 hours workshop
		Summer, 2022		8 hours workshop
		Summer, 2021		8 hours workshop
PHA 6894	Intro to Graduate Studies (1)	Spring/summer, 2023		1 lecture
		Spring/summer, 2022		1 lecture
		Spring/summer, 2021		1 lecture
		Spring/summer, 2020		1 lecture
		Spring/summer, 2019		1 lecture
PHA 6935	Life Cycle of a Drug (1)	Summer, 2022		1 lecture
		Summer, 2020		1 lecture
		Summer, 2019		1 lecture
		Summer, 2018		1 lecture
PHA 6935	Life Cycle of a Drug (1), cont.	Summer, 2017		1 lecture
PHA 6935	Spec. Topics (Peptide Chem. & Design) (1)	Spring, 2016		12 lectures/exams
<u>Pharmacy courses:</u>				
PHA-5787C	Patient Care 5 (6)	Spring, 2023		1 hour, lecture

* Does not include courses granting credit for research.

Course Number	Course Name (no. of credits)	Semester	Course-coordinator?	No. contact hrs.
PHA 5789C	Patient Care 7 (6)	Spring, 2024		~6 hours, lecture, active learning
		Spring, 2023		~6 hours, lecture, active learning
		Spring, 2022		~6 hours, lecture, active learning
		Spring, 2021		~6 hours, lecture, active learning
		Spring, 2020		~6 hours, lecture, active learning
		Spring, 2019		~6 hours, lecture, active learning
		Spring, 2018		~10 hours lectures, active learning
PHA 5788C	Patient Care 6 (3)	Fall, 2023		~5 hours lecture, active learning
		Fall, 2022		~5 hours lecture, active learning
		Fall, 2021		~5 hours lecture, active learning
		Fall, 2020		~5 hours lecture, active learning
		Fall, 2019		~5 hours lecture, active learning
		Fall, 2018		1 hour lecture
		Fall, 2017		~9 hours lectures, active learning
PHA 5878C	Patient Care 3 (6)	Fall, 2023		~14 hours lecture, active learning
		Fall, 2022		~14 hours lecture, active learning
		Fall, 2021		~14 hours lecture, active learning
		Fall, 2020		~14 hours lecture, active learning
		Fall, 2019		~14 hours lecture, active learning
		Fall, 2018		~9 hours lecture, active learning
		Fall, 2017		~14 hours lectures, active learning
		Fall, 2016		

Other:

Department of Neuroscience, GMS 6757, Introduction to Alzheimer's Disease Related Dementias, Clinical and Mechanistic Principles, Fall, 2019-2023, 1 lecture (drug discovery in Alzheimer's disease);

Dental school, DEN 6251, Clinical Management of Dental Pain, Fall, 2018- 2023 – 1 lecture (opioid abuse);

Dental school, special course Safe Controlled Substance Prescribing (required DEA training) for oral surgeons and residents, June 15, 2023, 1 lecture

Filmed interview for new interdisciplinary course from the Department of Chemistry, IDH3931 entitled Impact of Chemistry on Society, July, 2018.

University of Kansas (2001 – January, 2015):¹

Course Number	Course Name (no. of credits)	Semester	Course-coordinator?	No. contact hrs.
<u>Pharm.D. courses:</u>				
MDCM 601	Medicinal Biochemistry (4)	Fall, 2009		30 lectures/exams
		Fall, 2010		30 “ / “
		Fall, 2011		35 “ / “
		Fall, 2012		30 “ / “
		Fall, 2013	Yes	27 lectures/exams
		Fall, 2014		26 “ / “

Course Number	Course Name (no. of credits)	Semester	Course-coordinator?	No. contact hrs.
<u>Pharm.D. courses – cont.:</u>				
MDCM 603	Medicinal	Spring, 2010		5 lectures
	Biochemistry (3)	Spring, 2011		5 “
MDCM 626	Medicinal Chemistry II (3)	Spring, 2006	Yes	–
PTX 645	Neurological Basis of Addiction	Fall, 2014		1 lecture
		Fall, 2013		1 “
		Fall, 2012		1 “
		Spring, 2012		1 “
		Spring, 2011 (online)		1 “
		Spring, 2010		1 “
<u>Graduate courses:</u>				
MDCM 721	Intro. Med. Chem.	Fall, 2007		2 lectures
MDCM 775	Chemistry of the Nervous System (3)	Spring, 2014		3 hours
		Spring, 2012		3 hours
		Spring, 2010		3 hours
		Spring, 2008		6 hours
		Spring, 2006		3 hours
		Fall 2003		
MDCM 790	Drug Design (3)	Spring, 2014		10 lectures
		Spring, 2013		10 lectures
		Spring, 2012		9 lectures
		Spring, 2002 – 2011		8 lectures
MDCM 799	Seminar (1)	Spring, 2008	Yes	
		Fall, 2007		
		Spring, 2003		
		Fall, 2002		
MDCM 801	Issues of Scientific Integrity (1)	Fall 2005		1 lecture
		Fall 2003		
MDCM 804/ GS 804	Interdiscip. Seminar on Ethics In Science and Engineering (1-3)	Fall, 2007		2 hours
GS800	Preparing Future Faculty	2002		1 lecture (ethical issues encountered by faculty members)

¹2001 – Spring, 2009, Teaching only in graduate courses because of Independent Scientist Award from NIDA.

Participated in 5-day workshop on Ethics Education in Science and Engineering, January 16-18, 2007, March 1, 2007 and May 11, 2007.

VII. UNIVERSITY SERVICE

A. Committee Service

University of Florida (2015 – present)

University:

Department of Chemistry, Katrizky Chair faculty search, 2021-2022;

Department of Chemistry, computation chemistry faculty search, 2017-2018.

College of Pharmacy:

Endowed Chair review, 2021;

Tenure and Promotion Committee, 2017-2019;
Faculty Awards Committee, 2018 – present;
Search Committee, Chair of Department of Pharmacodynamics, 2016-2017;
Curriculum Committee, 2016 – March, 2017;
Graduate Education Task Force, 2016 – present;
Research Strategic Planning Taskforce, 2015 – present;
Potential PharmD student interviews, 2016 – present;
PharmD student advising, 2019 – present.
Department of Medicinal Chemistry:
Faculty search committees, co-chair 2022-2023, member 2021-2022, 2017-2018, 2016-2017 and 2015-2016;
Research scientist search committee, 2017.
Faculty mentoring committees: Assistant Professor Xingui Liu, 2024 – present;
Assistant Professor Guangrong Zheng, 2019 – 2022;
Assistant Professor Robert Huigens, 2016-2020.

University of Kansas (2001 – 2015):

University Committees and Service:

Animal Care Advisory Council, 2014 - 2015
HBC Emergency Preparedness Team, 2012 - 2015
KU internal grant review, Edward Mallinckrodt, Jr. Foundation grant submission, 2012
Five Year Review Committee for Pharmaceutical Chemistry Department Chair Dr. Christian Schoeneich, 2009-2010
Graduate School:
Graduate Council 2003 -2007
Executive Committee of the Graduate Council, 2004-2006, 2006-2007
Standing Committee on Faculty Appointments and Authorization, 2004
Ph.D. Completion Study, 2007
Recruiting Committee, 2005
Pew Scholar Selection Committee, 2004
Scholarship and Research Committee, 2004-2005
Five Year Review Committee for Higuchi Biosciences Center Director Dr. Eli Michaelis, 2006-2007

School and Department Committees and Service

School of Pharmacy:

PharmD curriculum revision subcommittee, 2013 – 2014
Curriculum committee, 2013 – 2014
Graduate Affairs committee, 2013 – 2014
Admissions committee, 2011-2013
New pharmacy building dedication committee, 2010
Graduate Affairs Committee, 2003-2007
Pharmacy Building Committee, 2004-2005
Executive Committee, 2001-2003
Subcommittee for GRF review, 2003
Financial Aid Awards Committee, 2002-2003

Department:

Co-organizer, Fall Retreat symposium “The optimization of drug physicochemical properties in early drug discovery,” Departments of Pharmaceutical Chemistry and Medicinal Chemistry, October 8, 2012.

Director of Graduate Studies, 2003 – August 2007

Developed and implemented two tracks (organic synthesis and biochemistry) for graduate students in the Medicinal Chemistry graduate program, 2006

Implemented research rotations for new graduate students in the Medicinal Chemistry graduate program, 2004

Submitted applications for graduate student funding:

Nominated graduate applicants for Self Graduate Fellowships

Three Self Graduate fellowships awarded to medicinal chemistry graduate students, 2006; one Self Graduate Fellowship awarded, 2007

Received 3-year supplemental scholarships for an incoming graduate student, 2005, 2006 and 2007

Submitted nominations of graduate applicants for several other university fellowships (Chancellor's/Honors Fellowship, Melki Graduate Fellowship), 2004 and 2006

Graduate recruiting at national meetings:

Graduate Recruiting Breakfasts at national American Chemical Society meetings:
August 25 – September 1, 2005, Washington, D.C.

March 26 – 30, 2006, Atlanta, GA

Attended Society for the Advancement of Chicano and Native American Scientists (SACNAS) meeting, September 2005, Denver, CO to recruit minority students

Graduate Admissions Committee, Chair 2003 – 2007; member 2007 – 2008, 2011 – 2014

Betty and Les Mitscher Prize for Excellence in Medicinal Chemistry Selection Committee, chair, 2012 and 2013

Strategic Plan Committee, member 2008

Center for Teaching Excellence Ambassador, 2002-2003

Faculty liaison, NIH remodeling grant for synthetic laboratories in old Malott Hall, 2003-2004

Safety officer, 2002-2003

Seminar coordinator, 2002-2003

Search committee, Assistant/Associate Professor, 2010-2011

Search committee, medicinal biochemistry laboratory instructor, 2011

Search committee, Professor/Associate Professor and Assistant/Associate Professor, 2006-2007

Search committee, Department Chair, 2002-2005

Search committee, Assistant/Associate Professor, 2002-2003

Search committee, teaching postdoctoral associate, chair, 2006-2007

Search committee, Graduate Student Recruiter, 2005-2006

Community Service

Organizer and moderator, “Opioid Awareness Discussion,” Gainesville, FL, September 18, 2018,
Presentation to Lawrence Welcome Club, “Designing New Drugs to Treat Disease,” Lawrence, KS, September 19, 2012.